## GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 13, 2004, 18:48:47; Search time 116.022 Seconds

(without alignments)

426.682 Million cell updates/sec

Title: US-10-010-942B-4 •

Perfect score: 719

Sequence: 1 MNFGLSLIFLVLVLKGVQCE.....DHYSGSSDYWGQGTTVTVSS 138

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A Geneseq 23Sep04:\*

1: geneseqp1980s:\*

2: geneseqp1990s:\*

3: geneseqp2000s:\*

4: geneseqp2001s:\*

5: geneseqp2002s:\*

6: geneseqp2003as:\*

7: geneseqp2003bs:\*

8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

			<del>ક</del>				
]	Result		Query			*** ***	
No. Score			Match Length D		DB	ID	Description
	1	718	99.9	138	<b>-</b> -	ABG76924	Abg76924 Mouse 3D6
	2	652	90.7	138	5	ABG76928	Abg76928 Humanised
	3	651	90.5	468	6	ABP58275	Abp58275 Humanised
	4	650	90.4	138	5	ABG76932	Abg76932 Humanised
	5	609.5	84.8	133	6	ABG74243	Abg74243 Mouse ant
	6	578.5	80.5	139	6	ABG74247	Abg74247 Mouse ant
	7	578	80.4	462	6	AA029869	Aao29869 Mouse ant
	8	578	80.4	462	7	ADJ79787	Adj79787 TRA-8 ant
	9	578	80.4	464	5	AAU72801	Aau72801 TRA-8 hea

10	573	79.7	138	2	AAR20064		MRK16-H c
11	569	79.1.	144	5	ABB79730	Abb79730 _	
12	568	79.0	139	2	AAR30480		hCEA spec
13	566	78.7	140	5	AAU76122		Mouse mon
14	564	78.4	139	2	AAR27053	Aar27053 .	
15	564	78.4	140	5	AAU76133		Mouse mAb
16	563	78.3	138	2	AAW03722	Aaw03722	Anti-huma
17	561	78.0	140	5	AAU76132	Aau76132	Mouse mAb
18	560	77.9	138	3	AAY32404	Aay32404	Mouse ant
19	559	77.7	140	6	ABG74241	Abg74241	Mouse ant
20	557.5	77.5	137	2	AAW57592	Aaw57592	Chimeric
21	557.5	77.5	137	2	AAW89625	Aaw89625	Mouse hum
22	557.5	77.5	137	3	AAY77513	Aay77513	Mouse ant
23	557.5	77.5	137	4	AAG67102	Aag67102 .	Amino aci
24	557.5	77.5	137	4	AAG64775	Aag64775	Mouse ant
25	557.5	77.5	137	4	AAG63393	Aag63393 .	Amino aci
26	557.5	77.5	137	5	ABB95208	Abb95208	Mouse joi
27	557.5	77.5	137	6	ABJ36667	Abj36667 .	Angiogene
28	557.5	77.5	137	8	AD033883	Ado33883	Murine pa
29	557	77.5	119	6	ABP58271	Abp58271	Humanised
30	557	77.5	449	6	ABP58273	Abp58273	Humanised
31	554.5	77.1	139	1	AAP90480	Aap90480	Chimeric
32	553	76.9	158	8	ADL27491	Adl27491	Amino aci
33	551	76.6	119	6	ABP58269	Abp58269	Humanised
34	551	76.6	158	2	AAW19579	Aaw19579	Mouse ant
35	551	76.6	477	2	AAR47450	Aar47450	T84.12 He
36	551	76.6	477	2	AAR47453	Aar47453	chiT84.12
37	550.5	76.6	141	8	AD043551	Ado43551	Amino aci
38	549	76.4	140	2	AAW21841	Aaw21841	Heavy cha
39	549	76.4	247	2	AAW11917	Aaw11917	Murine MA
40	547.5	76.1	141	8	AD043555	Ado43555	Amino aci
41	545	75.8	142	2	AAR30882	Aar30882	Antibody
42	542	75.4	140	7	ADC24966	Adc24966	Murine G2
43	542	75.4	140	7	ADK51721	Adk51721	Murine G2
44	539	75.0	136	2	AAR06251	Aar06251	Variable
45	539	75.0	138	3	AAY32406	Aay32406	Mouse ant

### ALIGNMENTS

```
RESULT 1
ABG76924
     ABG76924 standard; protein; 138 AA.
XX
AC
     ABG76924;
XX
DT
     05-NOV-2002 (first entry)
XX
DE
     Mouse 3D6 VH protein.
XX
KW
     Mouse; humanized; immunoglobulin; Ig; light chain; LC; heavy chain; HC;
     variable region complementarity determining region; 3D6; 10D5;
KW
     variable framework region; amyloidogenic disease; Alzheimer's disease;
KW
     amyloid deposit; variable light chain; VL; variable heavy chain; VH;
KW
     nootropic; neuroprotective; inhibitor of beta amyloid accumulation;
KW
KW
     Abeta.
```

```
XX
OS
    Mus musculus...
XX
    WO200246237-A2.
PN
XX
PD
    13-JUN-2002.
XX
    06-DEC-2001; 2001WO-US046587.
PF
XX
PR
    06-DEC-2000; 2000US-0251892P.
XX
     (NEUR-) NEURALAB LTD.
PA
     (AMHP ) WYETH.
PA
XX
PΙ
    Basi G, Saldanha J, Yednock T;
XX
DR
    WPI; 2002-519658/55.
DR
    N-PSDB; ABS59427.
XX
    Novel light/heavy chain of humanized immunoglobulin for treating
PT
    amyloidogenic disease, has 3D6/10D5 variable region complementarity
PT
    determining regions and variable framework region from human acceptor
PT
    immunoglobulin.
PT
XX
    Claim 68; Fig 2; 171pp; English.
PS
XX
    The present invention relates to new humanized immunoglobulin (Iq) light
CC
    chain (LC) or heavy chain (HC) comprising variable region complementarity
CC
    determining regions from 3D6/10D5 Ig LC or HC variable region sequence,
CC
    and variable framework region from human acceptor Ig LC or HC sequence.
CC
CC
    The invention is useful for preventing or treating an amyloidogenic
    disease or Alzheimer's disease in a patient. The invention is also useful
CC
CC
    for in vivo imaging amyloid deposits in a patient. The present amino acid
    sequence represents a mouse 3D6/10D5 variable light (VL) chain or
CC
CC
    variable heavy (VH) chain protein of the invention
XX
SQ
    Sequence 138 AA;
                                Score 718; DB 5; Length 138;
  Query Match
                        99.98;
  Best Local Similarity
                        99.38;
                                Pred. No. 7e-57;
                                               0;
 Matches 137; Conservative
                               1; Mismatches
                                                   Indels
                                                             0; Gaps
                                                                        0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qv
             61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
             121 YSGSSDYWGQGTTITVSS 138
Db
```

```
ABG76928 standard; protein; 138 AA.
ID
XX
    ABG76928;
AC
XX
DT
     05-NOV-2002 (first entry)
XX
DE
     Humanised 3D6 heavy chain variable region #1.
XX
KW
    Mouse; humanized; immunoglobulin; Iq; light chain; LC; heavy chain; HC;
KW
     variable region complementarity determining region; 3D6; 10D5;
KW
     variable framework region; amyloidogenic disease; Alzheimer's disease;
KW
     amyloid deposit; variable light chain; VL; variable heavy chain; VH;
     nootropic; neuroprotective; inhibitor of beta amyloid accumulation;
KW
KW
    Abeta.
XX
OS
    Homo sapiens.
OS
    Mus musculus.
OS
     Synthetic.
XX
    WO200246237-A2.
PN
XX
PD
     13-JUN-2002.
XX
PF
     06-DEC-2001; 2001WO-US046587.
XX
     06-DEC-2000; 2000US-0251892P.
PR
XX
PΑ
     (NEUR-) NEURALAB LTD.
PA
     (AMHP ) WYETH.
XX
PΙ
     Basi G,
              Saldanha J,
                          Yednock T;
XX
DR
    WPI; 2002-519658/55.
XX
PT
    Novel light/heavy chain of humanized immunoglobulin for treating
     amyloidogenic disease, has 3D6/10D5 variable region complementarity
PT
     determining regions and variable framework region from human acceptor
PT
PT
     immunoglobulin.
XX
    Claim 54; Page 155; 171pp; English.
PS
XX
CC
    The present invention relates to new humanized immunoglobulin (Ig) light
CC
     chain (LC) or heavy chain (HC) comprising variable region complementarity
CC
     determining regions from 3D6/10D5 Ig LC or HC variable region sequence,
CC
     and variable framework region from human acceptor Ig LC or HC sequence.
CC
     The invention is useful for preventing or treating an amyloidogenic
CC
     disease or Alzheimer's disease in a patient. The invention is also useful
CC
     for in vivo imaging amyloid deposits in a patient. The present amino acid
CC
     sequence represents a humanized 3D6 variable light (VL) chain or variable
CC
     heavy (VH) chain protein of the invention
XX
SQ
     Sequence 138 AA;
  Query Match
                          90.7%;
                                  Score 652; DB 5; Length 138;
  Best Local Similarity
                          89.1%; Pred. No. 6.2e-51;
  Matches 123; Conservative 9; Mismatches
                                                 6; Indels
                                                                 0; Gaps
                                                                              0;
```

```
1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              Db
          61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVRYDH 120
         121 YSGSSDYWGQGTTVTVSS 138
Qy
             121 YSGSSDYWGQGTLVTVSS 138
Db
RESULT 3
ABP58275
ID
    ABP58275 standard; protein; 468 AA.
XX
AC
    ABP58275;
XX
DT
    23-OCT-2003
                (revised)
    31-MAR-2003 (first entry)
DT
XX
DE
    Humanised 3D6 antibody heavy chain.
XX
KW
    Monoclonal antibody; 3D6; complementarity determining region; CDR; mouse;
    human; humanised antibody; antibody; Alzheimer's disease;
KW
KW
    Down's syndrome; cerebral amyloid angiopathy; neuroprotective; nootropic.
XX
OS
    Mus sp.
    Homo sapiens.
OS
OS
    Chimeric.
XX
FΗ
                   Location/Qualifiers
    Key
                   1. .19
FT
    Peptide
                   /label= Signal_peptide
FT
                   20. .468
FT
    Protein
FT
                   /label= Mature peptide
                   /note= "the mature heavy chain is claimed in Claim 5"
FT
FT
    Region
FT
                   /note= "heavy chain variable region, claimed in Claim 4"
FT
                   50. .54
    Region
                   /note= "CDR1"
FT
FT
    Region
                   69. .85
                   /note= "CDR2"
FT
FT
                   118. .127
    Region
                   /note= "CDR3"
FT
XX
PN
    WO200288306-A2.
XX
PD
    07-NOV-2002.
XX
    26-APR-2002; 2002WO-US011853.
PF
XX
    30-APR-2001; 2001US-0287539P.
PR
XX
     (ELIL ) LILLY & CO ELI.
PA
XX
```

```
ΡI
    Tsurushita N, Vasquez M;
XX
    WPI; 2003-183835/18.
DR
DR
    N-PSDB; ABZ24633, ABZ24635.
XX
PT
    New humanized forms of mouse 3D6 antibodies, useful for treating Down's
PT
    syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral
РТ
    amyloid angiopathy, or for inhibiting formation of or reducing Abeta
    plaque in the brain.
PT
XX
PS
    Disclosure; Page 13-14; 54pp; English.
XX
CC
    The present sequence is that of a preferred heavy chain of a humanised
CC
    antibody of the present invention. In the variable region of this
    sequence, the complementarity determining regions (CDRs) originate from
CC
    murine monoclonal antibody 3D6 and the framework region from human
CC
CC
    germline VH segment DP-45 and J segment JH4. Novel humanised antibodies
CC
    of the invention have CDRs from 3D6 and human framework sequences. These
CC
    humanised antibodies have binding affinities (affinity and epitope
    location) approximately the same as those of the mouse 3D6 antibody. The
CC
CC
    invention includes antibodies, single chain antibodies, and their
CC
    fragments, as well as nucleotide sequences, vectors, transformed host
    cells, and methods of using the humanised antibody to treat, prevent,
CC
CC
    alleviate, reverse or otherwise ameliorate symptoms and/or pathology
    associated with Down's syndrome, (pre-)clinical Alzheimer's disease or
CC
CC
     (pre-)clinical cerebral amyloid angiopathy, and to inhibit formation or
CC
    reduce Abeta plaque in the brain. (Updated on 23-OCT-2003 to standardise
CC
    OS field)
XX
    Sequence 468 AA;
SQ
 Query Match
                        90.5%; Score 651; DB 6; Length 468;
  Best Local Similarity
                        89.1%; Pred. No. 3e-50;
 Matches 123; Conservative
                               8; Mismatches
                                                7; Indels
                                                                         0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MNFGLSLIFLVLVLKGVQCEVQLVESGGGLVQPGGSLRLSCAGSGFTFSNYGMSWVRQAP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNSLYLQMNSLRAEDTAVYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
             Db
         121 YSGSSDYWGQGTLVTVSS 138
RESULT 4
ABG76932
    ABG76932 standard; protein; 138 AA.
XX
AC
    ABG76932;
XX
DT
    05-NOV-2002 (first entry)
XX
DE
    Humanised 3D6 heavy chain variable region #2.
```

```
XX
KW
    Mouse; humanized; immunoglobulin; Ig; light chain; LC; heavy chain; HC;
    variable region complementarity determining region; 3D6; 10D5;
KW
KW
    variable framework region; amyloidogenic disease; Alzheimer's disease;
    amyloid deposit; variable light chain; VL; variable heavy chain; VH;
KW
    nootropic; neuroprotective; inhibitor of beta amyloid accumulation;
KW
KW
XX
    Homo sapiens.
OS
OS
    Mus musculus.
OS
    Synthetic.
XX
    WO200246237-A2.
PN
XX
PD
    13-JUN-2002.
XX
    06-DEC-2001; 2001WO-US046587.
PF
XX
PR
    06-DEC-2000; 2000US-0251892P.
XX
     (NEUR-) NEURALAB LTD.
PA
PA
     (AMHP ) WYETH.
XX
PI
            Saldanha J,
    Basi G,
                         Yednock T;
XX
    WPI: 2002-519658/55.
DR
XX
PT
    Novel light/heavy chain of humanized immunoglobulin for treating
    amyloidogenic disease, has 3D6/10D5 variable region complementarity
PT
    determining regions and variable framework region from human acceptor
PT
PT
    immunoglobulin.
XX
PS
    Claim 55; Page 157; 171pp; English.
XX
CC
    The present invention relates to new humanized immunoglobulin (Ig) light
    chain (LC) or heavy chain (HC) comprising variable region complementarity
CC
CC
    determining regions from 3D6/10D5 Ig LC or HC variable region sequence,
CC
    and variable framework region from human acceptor Ig LC or HC sequence.
CC
    The invention is useful for preventing or treating an amyloidogenic
CC
    disease or Alzheimer's disease in a patient. The invention is also useful
CC
    for in vivo imaging amyloid deposits in a patient. The present amino acid
    sequence represents a humanized 3D6 variable light (VL) chain or variable
CC
CC
    heavy (VH) chain protein of the invention
XX
SO
    Sequence 138 AA;
 Query Match
                         90.4%;
                                Score 650; DB 5; Length 138;
                        88.4%;
 Best Local Similarity
                                Pred. No. 9.4e-51;
 Matches 122; Conservative 10; Mismatches
                                                 6; Indels
Qу
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRONS 60
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDH 120
Db
```

```
121 YSGSSDYWGQGTTVTVSS 138
              Db
          121 YSGSSDYWGQGTLVTVSS 138
RESULT 5
ABG74243
     ABG74243 standard; protein; 133 AA.
AC
     ABG74243;
XX
DT
     22-APR-2003 (first entry)
XX
DΕ
    Mouse antibody 3D8 heavy chain variable region.
XX
ΚW
     T-cell receptor; cytostatic; dermatological; neuroprotective;
KW
     immunostimulant; GD3; ganglioside antigen; MB3.6; PSMA; tumour; 3D8; 4D4;
KW
     3E11; prostate-specific membrane antigen; zeta signalling chain;
     CD8alpha hinge; cancer; melanoma; neuroendocrine tumour; prostate cancer;
KW
     small cell lung cancer; heavy chain variable region; mouse.
KW
XX
OS
     Mus sp.
XX
PN
     US2002132983-A1.
XX
     19-SEP-2002.
PD
XX
PF
     10-DEC-2001; 2001US-00006773.
XX
PR
     30-NOV-2000; 2000US-0250087P.
     30-NOV-2000; 2000US-0250089P.
PR
XX
PΑ
     (JUNG/) JUNGHANS R P.
XX.
PΙ
     Junghans RP;
XX
DR
     WPI; 2003-208946/20.
DR
     N-PSDB; ABX16569.
XX
     New chimeric molecule useful in treating patients with disorders, such as
PT
PT
     melanoma, neuroendocrine disorders, prostate and small cell lung cancer
PT
     comprises GD3 and/or PSMA binding domains of antibody.
XX
PS
     Disclosure; Page 12; 35pp; English.
XX
CC
     The invention relates to a chimaeric molecule comprising the GD3
CC
     (ganglioside antigen) binding domain of antibody MB3.6, with any of 3
     variable gene sequences, or the PSMA (prostate-specific membrane antigen)
CC
CC
     binding domain of antibody 3D8, 4D4 and 3E11, with variable gene
CC
     sequences, the zeta signalling chain of the T cell receptor and an
CC
     intervening CD8alpha hinge in which cysteine residues have been mutated.
     The chimaeric molecules expressed in T cells or NK cells or other
CC
     effector cells are useful in treating patients with cancers expressing
CC
CC
     the GD3 (MB3.6 derivatives) or PSMA antigen (3D8, 4D4, 3E11 derivatives),
CC
     and/or together with each other or with heterologous constructs to engage
CC
     additional stimulatory and functional properties of the effector cells to
```

```
enhance the antitumour therapeutic efficacy (claimed). They are
    particularly useful in disorders including melanoma, neuroendocrine
CC
CC
    tumours and prostate and small cell lung cancer. The present sequence
CC
    represents the mouse antibody 3D8 heavy chain variable region
XX
SO
    Sequence 133 AA;
                               Score 609.5; DB 6;
 Query Match
                        84.8%;
                                                   Length 133;
 Best Local Similarity
                        87.0%;
                                Pred. No. 4e-47;
 Matches 120; Conservative
                               6: Mismatches
                                                7;
                                                    Indels
                                                                 Gaps
                                                                         1;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVKVVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
QУ
             61 DKRLEWVASISSGGDSTFYADNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCARDDL 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
                    111111:1111
Db
         121 FN----WGQGTTLTVSS 133
RESULT 6
ABG74247
    ABG74247 standard; protein; 139 AA.
XX
AC
    ABG74247;
XX
DT
    22-APR-2003 (first entry)
XX
DE
    Mouse antibody 3E11 heavy chain variable region.
XX
    T-cell receptor; cytostatic; dermatological; neuroprotective;
KW
KW
    immunostimulant; GD3; ganglioside antigen; MB3.6; PSMA; tumour; 3D8; 4D4;
    3E11; prostate-specific membrane antigen; zeta signalling chain;
KW
    CD8alpha hinge; cancer; melanoma; neuroendocrine tumour; prostate cancer;
KW
KW
    small cell lung cancer; heavy chain variable region; mouse.
XX
OS
    Mus sp.
XX
PN
    US2002132983-A1.
XX
PD
    19-SEP-2002.
XX
    10-DEC-2001; 2001US-00006773.
PF
XX
PR
    30-NOV-2000; 2000US-0250087P.
    30-NOV-2000; 2000US-0250089P.
PR
XX
PA
    (JUNG/) JUNGHANS R P.
XX
PΙ
    Junghans RP;
XX
DR
    WPI; 2003-208946/20.
    N-PSDB; ABX16573.
DR
```

CC

```
XX
PT
    New chimeric molecule useful in treating patients with disorders, such as
    melanoma, neuroendocrine disorders, prostate and small cell lung cancer
PT
PΤ
     comprises GD3 and/or PSMA binding domains of antibody.
XX
PS
    Disclosure; Page 17; 35pp; English.
XX
CC
    The invention relates to a chimaeric molecule comprising the GD3
     (ganglioside antigen) binding domain of antibody MB3.6, with any of 3
CC
CC
     variable gene sequences, or the PSMA (prostate-specific membrane antigen)
CC
    binding domain of antibody 3D8, 4D4 and 3E11, with variable gene
CC
     sequences, the zeta signalling chain of the T cell receptor and an
CC
     intervening CD8alpha hinge in which cysteine residues have been mutated.
CC
     The chimaeric molecules expressed in T cells or NK cells or other
CC
     effector cells are useful in treating patients with cancers expressing
CC
     the GD3 (MB3.6 derivatives) or PSMA antigen (3D8, 4D4, 3E11 derivatives),
CC
     and/or together with each other or with heterologous constructs to engage
CC
     additional stimulatory and functional properties of the effector cells to
CC
    enhance the antitumour therapeutic efficacy (claimed). They are
    particularly useful in disorders including melanoma, neuroendocrine
CC
     tumours and prostate and small cell lung cancer. The present sequence
CC
CC
     represents the mouse antibody 3E11 heavy chain variable region
XX
SQ
    Sequence 139 AA;
 Query Match
                         80.5%;
                                Score 578.5; DB 6;
                                                    Length 139;
 Best Local Similarity
                         82.7%;
                                Pred. No. 2.6e-44;
 Matches 115; Conservative
                               6; Mismatches
                                               17;
                                                     Indels
                                                                          1:
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy .
             1 MNFGLSLIFLVLVLKGVQCEVKLVESGGDLMNPGASLKLSCAASGFSFSNYGMSWVRQTS 60.
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             Db
          61 DKRLEWVASISTGGANTFYPDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYFCARDSH 120
         121 YSGS-SDYWGQGTTVTVSS 138
Qу
               1
                    Db
         121 SVGCWFATWGQGTLVTVSA 139
RESULT 7
AA029869
    AAO29869 standard; protein; 462 AA.
ID
XX
    AAO29869;
AC
XX
DT
     27-AUG-2003 (first entry)
XX
DE
    Mouse anti-human DR5 antibody (TRA-8) heavy chain.
XX
KW
     Tumour necrosis factor; TNF-related apoptosis-inducing ligand; allergy;
     inflammatory disease; TRAIL receptor; systemic lupus erythematosus; DR4;
KW
     Hashimoto's disease; rheumatoid arthritis; inflammatory disease; cancer;
KW
     multiple sclerosis; graft-versus-host disease; arteriosclerosis; asthma;
KW
KW
     Goodpasture's syndrome; autoimmune disease; glomerular nephritis; DR5;
```

```
Crohn's disease; diabetes mellitus; antibody; mouse.
KW
XX
OS
    Mus sp.
XX
    WO2003037913-A2.
PN
XX
PD
    08-MAY-2003.
XX
    01-NOV-2002; 2002WO-US035333.
PF
XX
PR
    01-NOV-2001; 2001US-0346402P.
XX
PA
    (UABR-) UAB RES FOUND.
XX
ΡI
    Zhou T, Kimberly RP, Koopman WJ, Lobuglio AF, Buchsbaum DJ;
XX
DR
    WPI; 2003-441350/41.
DR
    N-PSDB; AAL60477.
XX
PT
    New purified antibody that specifically binds a TNF-related apoptosis-
PT
    inducing ligand receptor DR4 or DR5, useful for treating cancer,
    inflammatory disease or autoimmune disease in a subject, e.g. asthma or
PT
PT
    rheumatoid arthritis.
XX
PS
    Example 16; Page 224-225; 251pp; English.
XX
CC
    The invention relates to an antibody that specifically binds a tumour
CC
    necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor
CC
    DR4 or DR5. Antibodies of the invention are useful for selectively
CC
    inducing apoptosis in target cells expressing DR4, for inhibiting
CC
    proliferation of target cells expressing DR4 or for treating cancer,
CC
    inflammatory disease or autoimmune disease in a subject e.g. systemic
CC
    lupus erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-
CC
    versus-host disease, Goodpasture's syndrome, Crohn's disease, multiple
CC
    sclerosis, diabetes mellitus, allergy, asthma, arteriosclerosis or
CC
    glomerular nephritis. The present sequence is mouse anti-human DR5
CC
    antibody (TRA-8) heavy chain
XX
SQ
    Sequence 462 AA;
 Query Match
                        80.4%; Score 578; DB 6; Length 462;
 Best Local Similarity
                        81.2%; Pred. No. 1.1e-43;
 Matches 112; Conservative 10; Mismatches 16; Indels
                                                                        0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYVMSWVRQTP 60
QУ
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLOMSSLKSEDTALYYCVRYDH 120
             Db
          61 EKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRGD 120
         121 YSGSSDYWGQGTTVTVSS 138
Qу
              Db
         121 SMITTDYWGQGTTLTVSS 138
```

```
RESULT 8
ADJ79787 .
     ADJ79787 standard; protein; 462 AA.
XX
AC
     ADJ79787;
XX .
DΤ
     06-MAY-2004 (first entry)
XX
DE
     TRA-8 antibody heavy chain.
XX
KW
     nephrotropic; antiarteriosclerotic; cardiant; antiasthmatic;
KW
     antiallergic; antiinflammatory; antidiabetic; haemostatic;
KW
     neuroprotective; antiinfertility; immunosuppressive; dermatological;
KW
     antianaemic; antirheumatic; antiarthritic; thyromimetic; apoptosis;
     proliferation;
KW
     tumor necrosis factor-related apoptosis-inducing ligand receptor; TNF;
KW
KW
     TRAIL; synovial cell; lymphocyte; neutrophil;
KW
     systemic lupus erythematosus; Hashimoto's disease; rheumatoid arthritis;
KW
     graft-versus-host disease; Sjogren's syndrome; pernicious anemia;
KW
     Addison disease; scleroderma; Goodpasture's syndrome; Crohn's disease;
KW
     autoimmune hemolytic anemia; sterility; myasthenia gravis;
KW
     multiple sclerosis; Basedow's disease; thrombotic; thrombocytopenia;
     thrombopenia purpura; insulin dependent diabetes mellitus; allergy;
KW
KW
     asthma; atopic disease; arteriosclerosis; myocarditis; cardiomyopathy;
KW
     glomerular nephritis; hypoplastic anemia.
XX
OS
     Homo sapiens.
XX
     WO2003038043-A2.
PN
XX
     08-MAY-2003.
PD
XX
     25-OCT-2002; 2002WO-US034420.
PF
XX
     01-NOV-2001; 2001US-0346402P.
PR
PR
     24-JUN-2002; 2002US-0391478P.
XX
PA
     (UABR-) UAB RES FOUND.
XX
PI
     Zhou T, Ichikawa K, Kimberly RP, Koopman WJ, Oshumi J;
PΙ
     Lobuglio AF, Buchsbaum DJ;
XX
     WPI; 2003-421518/39.
DR
XX
PT
     Inducing apoptosis and inhibiting proliferation of target cells
PT
     expressing DR5, by contacting the target cell with an antibody that binds
     TNF-related apoptosis-inducing ligand receptor DR5 and with therapeutic
PT
PT
     agents.
XX
PS
     Example 16; SEQ ID NO 23; 274pp; English.
XX
CC
     The invention relates to a method of selectively inducing apoptosis in
CC.
     and inhibiting (M1) proliferation of target cells expressing DR5,
CC
     comprising contacting the cell with an antibody that specifically binds
CC
     tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
CC
     receptor DR5, where the antibody, in its soluble form, has in vivo and in
CC
     vitro apoptosis-inducing activity in the cell expressing DR5, and
```

```
CC
    contacting the cell with one or more therapeutic agents. M1 is useful for
CC
    inducing apoptosis in target cell and inhibiting proliferation of target
CC
    cell expressing DR5, where the target cell is an abnormally proliferating
CC
    synovial cells (e.g. rheumatoid arthritis synovial cell), activated
CC
    immune cell (e.g. activated lymphocyte), neutrophil, or virally infected
CC
    cell. M2 is useful for treating a subject having inflammatory and
CC
    autoimmune diseases. The inflammatory or autoimmune disease are selected
CC
    from systemic lupus erythematosus, Hashimoto's disease, rheumatoid
    arthritis, graft-versus-host disease, Sjogren's syndrome, pernicious
CC
CC
    anemia, Addison disease, scleroderma, Goodpasture's syndrome, Crohn's
CC
    disease, autoimmune hemolytic anemia, sterility, myasthenia gravis,
CC
    multiple sclerosis, Basedow's disease, thrombotic, thrombocytopenia,
CC
    thrombopenia purpura, insulin dependent diabetes mellitus, allergy,
CC
    asthma, atopic disease, arteriosclerosis, myocarditis, cardiomyopathy,
CC
    glomerular nephritis, and hypoplastic anemia. This sequence represents a
CC
    protein used in the method of the invention.
XX
    Sequence 462 AA;
SQ
 Query Match
                         80.4%; Score 578; DB 7; Length 462;
 Best Local Similarity
                         81.2%;
                                Pred. No. 1.1e-43;
 Matches 112; Conservative 10; Mismatches
                                              16;
                                                   Indels
                                                              0;
                                                                  Gaps
                                                                          0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYVMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 EKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRGD 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
QУ
                ::|||||||
         121 SMITTDYWGQGTTLTVSS 138
RESULT 9
AAU72801
    AAU72801 standard; protein; 464 AA.
XX
AC
    AAU72801;
XX
DT
    26-FEB-2002 (first entry)
XX
DΕ
    TRA-8 heavy chain.
XX
KW
    Tumour necrosis factor-related apoptosis-inducing ligand receptor; TRAIL;
KW
    TRAIL receptor DR5; cytostatic; apoptosis; cell proliferation;
KW
    autoimmune disease; systemic lupus erythematosus; Hashimoto's disease;
     rheumatoid arthritis; Sjogren's syndrome; Chron's disease; anaemia;
KW
KW
    Addison disease; scleroderma; Goodpasture's syndrome; sterility;
    myasthenia gravis; multiple sclerosis; Basedow's disease; diabetes;
KW
KW
    allergy; arteriosclerosis; myocarditis; cardiomyopathy;
KW
    glomerular nephritis; cancer; antibody; chromosome 8p21-22; TRA-8.
XX
OS
    Mus musculus.
```

XX

```
WO200183560-A1.
PN
XX
    08-NOV-2001.
PD
XX
    02-MAY-2001; 2001WO-US014151.
PF
XX
    02-MAY-2000; 2000US-0201344P.
PR
XX
PA
     (UABR-) UAB RES FOUND.
XX
PΙ
    Zhou T, Ichikawa K, Kimberly RP, Koopman WJ;
XX
DR
    WPI; 2002-049338/06.
DR
    N-PSDB; AAS97062.
XX
PT
    Novel antibody specific for tumor necrosis factor-related apoptosis-
PT
    inducing ligand, useful for inhibiting cell proliferation in cancer.
XX
PS
    Claim 26; Page 198-199; 229pp; English.
XX
CC
    The invention describes a novel antibody which recognizes a tumour
CC
    necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor
    DR5 (located on chromosome 8p21-22). The antibody has apoptosis-inducing
CC
CC
    activity to a cell expressing DR5 in vivo. It is also useful for
CC
    preparing a therapeutic for selective apoptosis of abnormal or
CC
    dysregulated cells, and for inhibiting cell proliferation in a cell,
CC
    preferably a human breast, ovary, colon, haematopoietic, prostate,
     lymphatic, lung, glioma or liver cancer cell. A therapeutic agent may
CC
     also be administered e.g. paclitaxel, taxol or cycloheximide. The
CC
CC
     antibody is used to treat an autoimmune disease, systemic lupus
CC
     erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-versus-
    host disease, Sjogren's syndrome, Chron's disease, pernicious anaemia,
CC
CC
    Addison disease, scleroderma, Goodpasture's syndrome, autoimmune
CC
    haemolytic anaemia, sterility, myasthenia gravis, multiple sclerosis,
    Basedow's disease, insulin-dependent diabétes mellitus, allergy, atopic
CC
CC
    disease, arteriosclerosis, myocarditis, cardiomyopathy, glomerular
    nephritis, hypoplastic anaemia, rejection after organ transplantation,
CC
     and numerous malignancies of lung, prostate, liver, ovary, lymphatic or
CC
    breast tissue. Peptides used to design primers for isolating heavy and
CC
     light chain cDNA of the mouse TRAIL (AAU72801 and AAU72802), TRA-8 are
CC
CC
     shown in AAU72799 and AAU72800
XX
    Sequence 464 AA;
SQ
  Query Match
                         80.4%;
                                Score 578; DB 5; Length 464;
  Best Local Similarity
                         81.2%; Pred. No. 1.1e-43;
  Matches 112; Conservative 10; Mismatches
                                              16; Indels
                                                              0; Gaps
                                                                          0;
Qy
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
             Db
           1 MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYVMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 EKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRGD 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
```

Db

```
RESULT 10
AAR20064
     AAR20064 standard; protein; 138 AA.
ΧX
AC
     AAR20064;
XX
DT
     24-OCT-2003
                  (revised)
DT
                  (revised)
     25-MAR-2003
DT
     27-MAR-1992 (first entry)
XX
DE
     MRK16-H chain.
XX
KW
     Monoclonal antibody; light; heavy; chain; cancer; drug resistance.
XX
OS
     Homo; sapiens.
OS
     Mus musculus.
OS
     Chimeric.
XX
PN
     JP03254691-A.
XX
PD
     13-NOV-1991.
XX
PF
     02-MAR-1990; 90JP-00051563.
XX
     02-MAR-1990;
                    90JP-00051563.
PR
XX
PΑ
     (GANK-) ZH GAN KENKYUKAI.
     (FUJI-) FUJITA GAKUEN GH.
PA
PA
     (NICA-) JAPAN FOUND CANCER RES.
XX
     WPI; 1992-002461/01.
DR
DR
     N-PSDB; AAQ20070.
XX
     Chimera antibody against drug resistant cancer - comprises variable
PT
PТ
     region homologous to region in mouse monoclonal antibody and constant
PT
     region homologous to region in human immunoglobulin.
XX
     Disclosure; Fig 4; 20pp; Japanese.
PS
XX
     A chimeric antibody against drug-resistant cancer consists of (1) a
CC
     variable region having an amino acid sequence homologous to a variable
CC
     region in the mouse monoclonal antibody against.,drug- resistance and (2)
CC
     a constant region having an amino acid sequence homologous to the
CC
     constant region in human immunoglobulin. The chimeric antibody
     selectively inhibits the growth of cancer cells showing drug resistance
CC
     or enhances the sensitivity to the drug. The antibody is very low in
CC
CC
     immunogenicity. The MRK16-L chain is shown in AAQ20071. (Updated on 25-
CC
     MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to standardise OS
CC
     field)
XX
SQ
     Sequence 138 AA;
```

```
Best Local Similarity
                        80.4%; Pred. No. 8.1e-44;
 Matches 111; Conservative
                              8; Mismatches 19; Indels
                                                                        0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLILKGVQCEVILVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             Db
          61 EKRLEWVATISSGGGNTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARYYR 120
         121 YSGSSDYWGQGTTVTVSS 138
QУ
             1
                   121 YEAWFASWGQGTLVTVSA 138
Db
RESULT 11
ABB79730
ID
    ABB79730 standard; protein; 144 AA.
XX
ΑĊ
    ABB79730;
XX
DT
    29-OCT-2002 (first entry)
XX
DE
    Anti-Streptococcus mutans surface antigen MAb SWLA3 VH.
XX.
KW
    Streptococcus mutans; monoclonal antibody; MAb; mouse; chimeric antibody;
    antibody; anticaries; transgenic plant; transgenic animal; caries;
KW
KW
    immunotherapy; therapy.
XX
OS
    Mus musculus.
XX
PN
    US2002068066-A1.
XX
PD
    06-JUN-2002.
XX
    15-JUN-2001; 2001US-00881823.
PF
XX
PR
    20-AUG-1999;
                  99US-00378577.
XX
PΑ
     (SHIW/) SHI W.
PA
     (MORR/) MORRISON S L.
     (TRIN/) TRINH K.
PA
     (WIMS/) WIMS L.
PA
     (CHEN/) CHEN L.
PΑ
PA
     (ANDE/) ANDERSON M H.
XX
PΙ
    Shi W, Morrison SL,
                         Trinh K, Wims L, Chen L,
                                                  Anderson MH;
XX
DR
    WPI; 2002-565838/60.
DR
    N-PSDB; ABN84611.
XX
PT
    Treatment and prevention of dental caries in mammals, in particular
PT
    humans by orally administering genetically engineered or purified
    antibodies that bind to surface antigens of carcinogenic organisms.
PT
XX
PS
    Claim 14; Fig 3B; 30pp; English.
```

```
XX
    The present sequence is the protein sequence of the heavy chain variable
CC
CC
    region (VH) of the murine monoclonal antibody SWLA3 (IgG), which binds
CC
    specifically to the surface antigens of cariogenic type c Streptococcus
    mutans (ATCC 25175). The monoclonal antibody is produced by SWLA3 (ATCC
CC
    HB 12558) hybridoma cells. In an example from the invention, chimeric
CC
CC
    monoclonal antibody TEFE was produced comprising SWLA3 variable regions
    and human antibody constant regions. Such chimeric monoclonal antibodies
CC
CC
    can be used to prevent or treat dental caries in humans. The antibodies
CC
    engage the effector apparatus of the human immune system when they bind
CC
    cariogenic organisms, resulting in their destruction. The chimeric
CC
    antibodies may be produced in edible plants, in transgenic animals, or in
CC
    chicken eggs for oral ingestion
XX
SQ
    Sequence 144 AA;
 Query Match
                        79.1%; Score 569; DB 5; Length 144;
 Best Local Similarity
                        78.2%; Pred. No. 2e-43;
 Matches 111; Conservative 11; Mismatches 16; Indels
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MDFGLSLVFLVLTLKGVQCDVKLVESGGGLVNPGGSLKLSCAASGFTFSSYTMSWVRQTP 60
Qу
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
             Db
          61 EKRLEWVASISSGGTYTYYPDSVKGRFTISRDNAKNTLYLQMTSLKSEDTAMYYCSRDDG 120
         118 -YDHYSGSSDYWGQGTTVTVSS 138
Qy
              Db
         121 SYGSYYYAMDYWGQGTSVTVSS 142
RESULT 12
AAR30480
ID
    AAR30480 standard; protein; 139 AA.
XX
AC
    AAR30480;
XX
DT
    06-MAY-1993 (first entry)
XX
DE
    hCEA specific mouse heavy chain variable chain region.
XX
KW
    Chimeric antibody; human cancer embryonal antigen; treatment; diagnosis;
KW
    cancer.
XX
OS
    Mus musculus.
XX
FH
    Key
                   Location/Qualifiers
FT
    Peptide
                   1. .19
FT
                   /note= "signal peptide"
FT
                   20. .139
    Protein
FT
                   /note= "mature peptide"
XX
PN
    JP04330295-A.
XX
PD
    18-NOV-1992.
```

```
XX
PF
    28-DEC-1990; 90JP-00408811.
XX
PR
    28-DEC-1990;
                   90JP-00408811.
XX
     (MITU ) MITSUBISHI KASEI CORP.
PΑ
XX
DR
    WPI; 1993-003502/01.
    N-PSDB; AAQ33052.
DR
XX
PT
    Mouse-human chimeric antibody for diagnosis and treatment of cancer -
PT
    obtd. by combining variable region of mouse antibody specifically
PT
    combining to human cancer embryonic antigen with constant region of human
РΤ
    antibody.
XX
PS
    Disclosure; Page 6; 10pp; Japanese.
XX
CC
    The sequence is that of the heavy chain variable region of a mouse
CC
    antibody specific to human cancer embryonal antigen (hCEA). The region is
    used, with the corresponding mouse light chain variable region and the
CC
CC
    constant region of a human antibody, to prepare a mouse-human chimeric
    antibody which can be used for the diagnosis and treatment of cancer
CC
XX
SQ
    Sequence 139 AA;
 Query Match
                        79.0%; Score 568; DB 2; Length 139;
 Best Local Similarity
                        80.6%; Pred. No. 2.3e-43;
 Matches 112; Conservative 10; Mismatches 15; Indels
                                                                        2;
Qy
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRONS 60
             1 \ \mathtt{MNFGFSLIFLVLVLKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTP} \ \ 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLOMSSLKSEDTALYYCVRYDH 120
Qу
             Db
          61 EKRLEWVASITSDGS-TYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARVHY 119
         121 Y-SGSSDYWGQGTTVTVSS 138
Qy
             Db
         120 YDSPAMDYWGQGTSVTVSS 138
RESULT 13
AAU76122
ID
    AAU76122 standard; protein; 140 AA.
XX
AC
    AAU76122:
XX
DT
    08-MAY-2002 (first entry)
XX
DE
    Mouse monoclonal antibody 26-2F heavy chain variable region.
XX
KW
    Mouse; monoclonal antibody; heavy chain variable region; VH; angiogenin;
KW
    26-2F; angiogenesis; tumour; cancer; retinopathy;
KW
    ocular neovascular disease; vitamin A deficiency; syphilis;
KW
    Kaposi's sarcoma; rheumatoid arthritis; macular degeneration;
KW
    sickle cell anaemia; Paget's disease; mycobacterial infection;
```

KW osteoarthritis; graft versus host disease; autoimmune disease; ΚW type I diabetes; multiple sclerosis; systemic lupus erythematosus; myasthenia gravis. KW XX OS Mus sp. XX FΗ Location/Qualifiers Key FTPeptide 1. .19 /label= Signal peptide FTFTProtein 20. .140 FT/label= Mature VH FT50. .54 Region FT/label= Complementarity determining region FT /note= "This region is specifically claimed in claim 3" FT69. .85 Region /label= Complementarity determining region FTFT/note= "This region is specifically claimed in claim 3" FTRegion FT/label= Complementarity determining region FT/note= "This region is specifically claimed in claim 3" XX PNUS2002010320-A1. XX PD24-JAN-2002. XX 05-APR-1999; PF99US-00286240. XX PR05-APR-1999; 99US-00286240. XX PA (FETT/) FETT J W. XX PΙ Fett JW; XX DR WPI; 2002-187790/24. DR N-PSDB; ABK15270. XX PTNew antibody immunologically reactive to angiogenin useful for inhibiting PTangiogenesis and for treating conditions associated with abnormal PTangiogenesis e.g. cancer, ocular neovascular disease, rheumatoid PTarthritis. XX PS Claim 6; Page 14; 20pp; English. XX CC The invention relates to an antibody immunologically reactive to CCangiogenin or a fragment of angiogenin comprising light and heavy chain CC nonhuman-derived complementarity determining regions having a binding CC affinity to the angiogenin or its fragment in combination with human CC derived polypeptide regions (e.g. mouse monoclonal antibody 26-2F). Also CC included are an expression vector comprising a nucleic acid encoding the CC antibody and a host cell transformed with the vector. The antibody or its fragment is useful for inhibiting the angiogenic activity of angiogenin. CC CC The antibody is useful for treating a tumour in humans, by inhibiting, CCprohibiting, reducing or eliminating a tumour growth, or inhibiting the CCability of circulating tumour cell to form a vascularised tumour mass. The antibody is useful for treating a mammal with abnormal or unwanted CC CC angiogenesis, including cancer, and other diseases mediated by angiogenesis, including ocular neovascular disease, diabetic retinopathy, CC

```
CC
     retinopathy of prematurity, corneal graft rejection, neovascular glaucoma
CC
     and retrolental fibroplasia, and other diseases associated with corneal
CC
    neovascularisation including epidemic keratoconjuctivitis, vitamin A
CC
    deficiency, contact lens overwear, atopic keratitis, superior limbic
CC
     keratitis, syphilis, mycobacteria infections, lipid degeneration,
CC
     chemical burns, bacterial ulcers, fungal ulcers, herpes simplex
CC
     infections, herpes zoster infections, protozoan infections, Kaposi's
CC
     sarcoma, Mooren ulcer, rheumatoid arthritis, polyarteritis, trauma,
CC
    Wegener's sarcoidosis, Scleritis, Steven Johnson's disease, and corneal
CC
    graph rejection. Diseases associated with retinal/choroidal
CC
    neovascularisation include macular degeneration, sickle cell anaemia,
CC
     sarcoid, Paget's disease, mycobacterial infections, Bechets disease,
     trauma, osteoarthritis, Osler-Weber-Rendu disease, graft versus host
CC
CC
    disease, transplant rejection, autoimmune diseases such as type I
CC
    diabetes, multiple sclerosis, systemic lupus erythematosus, and
CC
    myasthenia gravis. The present sequence is the heavy chain variable
CC
     region of mouse monoclonal antibody 26-2F
XX
SQ
    Sequence 140 AA;
                         78.7%;
  Query Match
                                Score 566; DB 5; Length 140;
                        79.3%;
  Best Local Similarity
                                Pred. No. 3.5e-43;
 Matches 111; Conservative
                              13; Mismatches
                                              14;
                                                    Indels
                                                              2;
                                                                         2;
QУ
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
             Db
           1 MDFGLSWVFLVLILKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRY-D 119
Qy
             61 EKRLEWVATISSGGGNTYYPDSVKGRFTISRDIAKNTLYLQMSSLRSEDTALYYCTRLGD 120
Db
         120 H-YSGSSDYWGQGTTVTVSS 138
Qу
             : |: : |||||||
Db
         121 YGYAYTMDYWGQGTSVTVSS 140
RESULT 14
AAR27053
ID
    AAR27053 standard; protein; 139 AA.
XX
AC
    AAR27053;
XX
DT-
    01-MAR-1993 (first entry)
XX
DE
    Anti-CEA specific heavy chain variable region.
XX
KW
    Human; carcinoembryonic antigen; heavy chain; light chain; variable;
KW
     region; diagnostic; tumour; markers; targetting.
XX
OS
    Mus musculus.
XX
FH
    Key
                    Location/Qualifiers
FT
    Peptide
                    1. .19
FT
                    /note= "signal peptide"
FT
                    20. .139
    Protein
FT
                    /note= "mature peptide"
```

```
XX
PN
     JP04234987-A.
XX
PD
    24-AUG-1992:
XX
    28-DEC-1990;
PF
                   90JP-00408810.
XX
PR
    28-DEC-1990;
                  90JP-00408810.
XX
PA
     (MITU ) MITSUBISHI KASEI CORP.
XX
DR
    WPI; 1992-327631/40.
DR
    N-PSDB; AAQ28746.
XX
PT
    New DNA fragments encoding variable regions of ABS specific for human CEA
PT
    - for diagnosing and monitoring tumours, as tumour markers and for
PT
    treatment of tumours.
XX
PS
    Disclosure; Fig 1; 7pp; Japanese.
XX
CC
    The anti-CEA murine monoclonal antibody heavy chain variable region was
    obtd. by screening a cDNA library prepd. from mRNA obtd. from hybridomas
CC
    producing anti-CEA-specific antibodies with a probe based on the constant
CC
    region of the H-chain. The antibodies reacts specifically with human CEA
CC
    and are useful as a diagnostic agents, as tumour markers for digestive
CC
    organs, for diagnosis of malignant tumours; for monitering after cancer
CC
    operations, to follow up bloodless therapy or as therapeutic agents in
CC
CC
    passive immune therapy and targetting therapy. See also AAR27054
XX
SQ
    Sequence 139 AA;
 Query Match
                        78.4%; Score 564; DB 2; Length 139;
 Best Local Similarity
                        79.9%; Pred. No. 5.3e-43;
 Matches 111; Conservative 11; Mismatches 15; Indels
                                                                        2;
                                                                Gaps
Qу
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
             Db
           1 MNFGFSLIFLVLVLKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             Db
          61 EKRLEWVASITSDGS-TYYPDSVKGRFTISRDNARNILYLQMSSLRSEETAMYYCARVHY 119
Qу
         121 Y-SGSSDYWGQGTTVTVSS 138
             Db
         120 YDSPAMDYWGOGTSVTVSS 138
RESULT 15
AAU76133
ΙD
    AAU76133 standard; protein; 140 AA.
XX
AC
    AAU76133;
XX
DT
    08-MAY-2002 (first entry)
XX
    Mouse mAb 26-2F heavy chain variable region mutant E59Y.
DE
```

XX ΚW Mouse; angiogenin; angiogenesis; tumour; cancer; retinopathy; KW ocular neovascular disease; vitamin A deficiency; syphilis; KW Kaposi's sarcoma; rheumatoid arthritis; macular degeneration; KW sickle cell anaemia; Paget's disease; mycobacterial infection; KW osteoarthritis; graft versus host disease; autoimmune disease; KW type I diabetes; multiple sclerosis; systemic lupus erythematosus; KW myasthenia gravis; mutant; mutein; monoclonal antibody; 26-2F; KW heavy chain variable region; E59Y. XXOS Mus sp. OS Synthetic. XX FH Key Location/Qualifiers FTPeptide 1. .19 FT/label= Signal\_peptide FT Protein 20. .140 /label= Mature\_VH FTMisc-difference 59 FT/note= "Wild-type Glu substituted by Tyr" FTXX PNUS2002010320-A1. XX 24-JAN-2002. PDXX PF 05-APR-1999; 99US-00286240. XX 05-APR-1999; PR 99US-00286240. XX PA(FETT/) FETT J W. XX PΙ Fett JW; XX DR WPI; 2002-187790/24. XX PTNew antibody immunologically reactive to angiogenin useful for inhibiting PT angiogenesis and for treating conditions associated with abnormal PTangiogenesis e.g. cancer, ocular neovascular disease, rheumatoid PTarthritis. XX PS Claim 11; Page; 20pp; English. XX CCThe invention relates to an antibody immunologically reactive to CC angiogenin or a fragment of angiogenin comprising light and heavy chain CCnonhuman-derived complementarity determining regions having a binding CC affinity to the angiogenin or its fragment in combination with human CCderived polypeptide regions (e.g. mouse monoclonal antibody 26-2F). Also CCincluded are an expression vector comprising a nucleic acid encoding the CCantibody and a host cell transformed with the vector. The antibody or its CC fragment is useful for inhibiting the angiogenic activity of angiogenin. The antibody is useful for treating a tumour in humans, by inhibiting, CC CCprohibiting, reducing or eliminating a tumour growth, or inhibiting the CCability of circulating tumour cell to form a vascularised tumour mass. CCThe antibody is useful for treating a mammal with abnormal or unwanted CC angiogenesis, including cancer, and other diseases mediated by angiogenesis, including ocular neovascular disease, diabetic retinopathy,

retinopathy of prematurity, corneal graft rejection, neovascular glaucoma

CC

CC

```
CC
    and retrolental fibroplasia, and other diseases associated with corneal
CC
    neovascularisation including epidemic keratoconjuctivitis, vitamin A
CC
    deficiency, contact lens overwear, atopic keratitis, superior limbic
CC
    keratitis, syphilis, mycobacteria infections, lipid degeneration,
    chemical burns, bacterial ulcers, fungal ulcers, herpes simplex
CC
CC
    infections, herpes zoster infections, protozoan infections, Kaposi's
CC
    sarcoma, Mooren ulcer, rheumatoid arthritis, polyarteritis, trauma,
    Wegener's sarcoidosis, Scleritis, Steven Johnson's disease, and corneal
CC
CC
    graph rejection. Diseases associated with retinal/choroidal
    neovascularisation include macular degeneration, sickle cell anaemia,
    sarcoid, Paget's disease, mycobacterial infections, Bechets disease,
CC
CC
    trauma, osteoarthritis, Osler-Weber-Rendu disease, graft versus host
CC
    disease, transplant rejection, autoimmune diseases such as type I
CC
    diabetes, multiple sclerosis, systemic lupus erythematosus, and
CC
    myasthenia gravis. The present sequence represents the E59Y mutant of the
CC
    mouse monoclonal antibody 26-2F light chain variable region. Note: The
CC
    present sequence is not shown in the specification but was created by the
CC
    indexer using the sequence appearing as AAU76122 and the information in
CC
    the claims
XX
SQ
    Sequence 140 AA;
 Query Match
                        78.4%;
                               Score 564; DB 5; Length 140;
 Best Local Similarity
                        79.3%;
                                Pred. No. 5.3e-43;
 Matches 111; Conservative 13; Mismatches
                                               14; Indels
                                                             2;
                                                                 Gaps
                                                                         2;
Qу
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
             Db
           1 MDFGLSWVFLVLILKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVROYP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLOMSSLKSEDTALYYCVRY-D 119
Qу
             Db
          61 EKRLEWVATISSGGGNTYYPDSVKGRFTISRDIAKNTLYLQMSSLRSEDTALYYCTRLGD 120
         120 H-YSGSSDYWGOGTTVTVSS 138
Qу
             : 1: : ||||||:||:||
Db
         121 YGYAYTMDYWGQGTSVTVSS 140
```

Search completed: December 13, 2004, 19:13:31

Job time : 125.022 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 13, 2004, 19:05:17; Search time 28.6222 Seconds

(without alignments)

319.748 Million cell updates/sec

Title: US-10-010-942B-4

Perfect score: 719

Sequence: 1 MNFGLSLIFLVLVLKGVQCE......DHYSGSSDYWGQGTTVTVSS 138

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 segs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:\*

1: /cgn2 6/ptodata/1/iaa/5A COMB.pep:\*

2: /cgn2 6/ptodata/1/iaa/5B COMB.pep:\*

3: /cgn2 6/ptodata/1/iaa/6A COMB.pep:\*

4: /cgn2 6/ptodata/1/iaa/6B COMB.pep:\*

5: /cgn2 6/ptodata/1/iaa/PCTUS COMB.pep:\*

6: /cgn2 6/ptodata/1/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

			<del>2</del>				
Re	sult		Query				
	No.	Score	Match	Length	DB	ID	Description
	1	566.5	78.8	135	3	US-08-579-378A-16	Sequence 16, Appl
	2	563	78.3	138	2	US-08-379-057-14	Sequence 14, Appl
	.3	551	76.6	158	2	US-08-653-402B-6	Sequence 6, Appli
	4	549	76.4	140	3	US-08-836-561-23	Sequence 23, Appl
	5	549	76.4	140	4	US-09-434-122-23	Sequence 23, Appl
	6	549	76.4	247	5	PCT-US94-07659-2	Sequence 2, Appli
	7	545.5	75.9	135	3	US-08-579-378A-20	Sequence 20, Appl
	8	541	75.2	136	3	US-08-976-183A-33	Sequence 33, Appl
	9	540	75.1	136	3	US-08-976-183A-31	Sequence 31, Appl
	10	537	74.7	136	3	US-08-976-183A-32	Sequence 32, Appl
	11	536	74.5	136	3	US-08-976-183A-34	Sequence 34, Appl

```
12
      535
            74.4
                    136 1 US-08-253-877C-57
                                                      Sequence 57, Appl
13
      535
            74.4
                    136 2
                            US-08-452-164A-57
                                                      Sequence 57, Appl
      535
14
            74.4
                    138 1
                            US-08-053-171-7
                                                      Sequence 7, Appli
15
      535
            74.4
                    138 1
                                                      Sequence 11, Appl
                            US-08-053-171-11
16
      535
            74.4
                    158 2
                            US-08-653-402B-10
                                                      Sequence 10, Appl
                                                      Sequence 96, Appl
17
    514.5
            71.6
                    139
                         1
                            US-08-129-930B-96
18
    514.5
            71.6
                    139
                                                      Sequence 51, Appl
                         3
                            US-08-134-346A-51
19
    514.5
            71.6
                    139 3
                            US-08-976-288A-96
                                                      Sequence 96, Appl
20
      513
            71.3
                    170 2
                            US-08-652-558-40
                                                      Sequence 40, Appl
21
    512.5
            71.3
                    159 2
                            US-08-653-402B-2
                                                      Sequence 2, Appli
22
    497.5
            69.2
                    255 2
                            US-07-690-192-4
                                                      Sequence 4, Appli
23
    494.5
                                                      Sequence 1, Appli
            68.8
                    463 4
                            US-09-472-087-1
                    463 4
24
    494.5
            68.8
                            US-09-472-087-63
                                                      Sequence 63, Appl
25
    494.5
            68.8
                    463 4
                            US-09-472-087-64
                                                      Sequence 64, Appl
26
      493
            68.6
                    464 4
                            US-09-472-087-2
                                                      Sequence 2, Appli
27
      493
            68.6
                    464 4
                            US-09-472-087-66
                                                      Sequence 66, Appl
28
    490.5
            68.2
                    135 5
                            PCT-US95-07302-8
                                                      Sequence 8, Appli
29
      486
            67.6
                    130 4
                            US-09-225-322B-8
                                                      Sequence 8, Appli
30
                                                      Sequence 8, Appli
      486
            67.6
                    130 4
                            US-09-764-304-8
                    122 1
31
    484.5
            67.4
                            US-07-634-278-48
                                                      Sequence 48, Appl
    484.5
32
            67.4
                    122
                            US-08-477-728-48
                        1
                                                      Sequence 48, Appl
    484.5
                                                      Sequence 48, Appl
33
            67.4
                    122
                        1
                            US-08-474-040-48
34
    484.5
            67.4
                                                      Sequence 48, Appl
                    122 1
                            US-08-487-200-48
35
    484.5
            67.4
                    122 3 US-08-484-537-48
                                                      Sequence 48, Appl
36
      484
           67.3
                    130 4 US-09-225-322B-18
                                                      Sequence 18, Appl
37
      484
            67.3
                    130 4 US-09-764-304-18
                                                      Sequence 18, Appl
38
    482.5
            67.1
                    135 3 US-08-619-491-8
                                                      Sequence 8, Appli
39
    482.5
            67.1
                    463 4 US-09-472-087-4
                                                      Sequence 4, Appli
40
    482.5
                    463 4
            67.1
                           US-09-472-087-68
                                                      Sequence 68, Appl
                    456 4
    480.5
41
            66.8
                            US-09-495-880A-11
                                                      Sequence 11, Appl
                    135 3
42
    478.5
            66.6
                            US-08-619-491-4
                                                      Sequence 4, Appli
    478.5
43
            66.6
                    135 5
                            PCT-US95-07302-4
                                                      Sequence 4, Appli
44
      477
           66.3
                    239 2 US-08-553-497A-18
                                                      Sequence 18, Appl
45
      475
            66.1
                    123 3 US-09-344-587-13
                                                      Sequence 13, Appl
```

### ALIGNMENTS

```
RESULT 1
US-08-579-378A-16
; Sequence 16, Application US/08579378A
; Patent No. 6210671
  GENERAL INFORMATION:
    APPLICANT: Co, Man Sung
    TITLE OF INVENTION: Humanized Antibodies Reactive with
    TITLE OF INVENTION: L-Selectin
    NUMBER OF SEQUENCES: 20
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Townsend and Townsend and Crew
      STREET: One MarketPlaza, Steuart Tower, Suite 2000
      CITY: San Francisco
      STATE: California
      COUNTRY: USA
      ZIP: 94105
;
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
```

```
COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/579,378A
      FILING DATE: 27-DEC-1995
      CLASSIFICATION: 424
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/160,074
      FILING DATE: 30-NOV-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/983,946
      FILING DATE: 01-DEC-1992
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: EP 95112895.8
      FILING DATE: 17-AUG-1995
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: EP 95114696.8
      FILING DATE: 19-SEP-1995
    ATTORNEY/AGENT INFORMATION:
      NAME: Liebescheutz, Joe O.
      REGISTRATION NUMBER: 37,505
      REFERENCE/DOCKET NUMBER: 11823-002220
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-326-2400
      TELEFAX: 415-326-2422
  INFORMATION FOR SEO ID NO: 16:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 135 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-579-378A-16
                       78.8%; Score 566.5; DB 3; Length 135;
 Query Match
 Best Local Similarity 81.2%; Pred. No. 1.4e-52;
 Matches 112; Conservative 8; Mismatches 15; Indels
                                                               Gaps
                                                                      2;
Qy .
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRONS 60
            Db
          1 MNFGSSLIFLVLVLKGVQCEVKLVESGGGLVKPGGSLKLACAASGFTFSTYAMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLOMSSLKSEDTALYYCVRYDH 120
Qγ
            Db
         61 EKRLEWVASI-STGGSTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCAR--D 117
         121 YSGSSDYWGQGTTVTVSS 138
Qy
            Db
         118 YDGYFDYWGQGTTLTVSS 135
RESULT 2
US-08-379-057-14
; Sequence 14, Application US/08379057
; Patent No. 5876950
  GENERAL INFORMATION:
    APPLICANT: Siadak, Anthony W.
```

```
APPLICANT: Hollenbaugh, Diane L.
               Gilliland, Lisa K.
    APPLICANT:
    APPLICANT:
               Gordon, Marcia L.
    APPLICANT: Bajorath, Jurgen
    APPLICANT: Aruffo, Alejandro A.
    TITLE OF INVENTION: Monoclonal Antibodies Specific For
    TITLE OF INVENTION: Different Epitopes of Human gp39 and Methods For Their
;
Use
    TITLE OF INVENTION: In Diagnosis and Therapy
;
    NUMBER OF SEQUENCES: 57
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Bristol-Myers Squibb Company
      STREET: 3005 First Avenue
      CITY: Seattle
      STATE: Washington
      COUNTRY: USA
      ZIP: 98121
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/379,057
      FILING DATE: 26-JAN-1995
      CLASSIFICATION: 435
    ATTORNEY/AGENT INFORMATION:
      NAME: Poor, Brian W.
      REGISTRATION NUMBER: 32,928
      REFERENCE/DOCKET NUMBER: ON0133-
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (206) 727-3670
      TELEFAX: (206) 727-3601
  INFORMATION FOR SEQ ID NO: 14:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 138 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
    FRAGMENT TYPE: N-terminal
US-08-379-057-14
 Query Match
                       78.3%; Score 563; DB 2; Length 138;
 Best Local Similarity
                      79.1%; Pred. No. 3.3e-52;
                                                                      2;
 Matches 110; Conservative 11; Mismatches
                                             16;
                                                  Indels
                                                               Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGFSLIFLVLVLKGVQCEVKLVESGGGLVKPGGSLKLSCTTSGFTFNNYAMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR-YD 119
Qy
             61 EKRLEWVASI-SSGDSTYYPDSVRGRFTISRDNARNILYLQMSSLRSEDTAMYYCARHYD 119
Db
         120 HYSGSSDYWGQGTTVTVSS 138
Qу
             Db
         120 YDSYAMDYWGQGTSVTVSS 138
```

```
RESULT 3
US-08-653-402B-6
; Sequence 6, Application US/08653402B
; Patent No. 5969107
   GENERAL INFORMATION:
    APPLICANT: CARCELLER, Ana
    APPLICANT: ROSELL, Elisabet
    APPLICANT: GOMEZ, Alicia
    APPLICANT: ADEN, Jaume
    APPLICANT: PIULATS, Jaume
    TITLE OF INVENTION: Anti-idiotypic antibodies which induce an TITLE OF INVENTION: immune response against epidermal growth factor
receptor.
    NUMBER OF SEQUENCES: 13
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Millen, White, Zelano & Branigan, P.C.
      STREET: 2200 Clarendon Boulevard, Suite 1400
      CITY: Arlington
       STATE: Virginia
      COUNTRY: U.S.A.
      ZIP: 22201
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/653,402B
      FILING DATE: 24-MAY-1996
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: EP 95107967.2
       FILING DATE: 26-MAY-1995
    ATTORNEY/AGENT INFORMATION:
      NAME: Lebovitz, Richard M.
      REGISTRATION NUMBER: 37,067
      REFERENCE/DOCKET NUMBER: MERCK 1781
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 703-243-6333
      TELEFAX: 703-243-6410
   INFORMATION FOR SEQ ID NO:
     SEQUENCE CHARACTERISTICS:
       LENGTH: 158 amino acids
       TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-653-402B-6
                          76.6%; Score 551; DB 2; Length 158;
  Query Match
  Best Local Similarity
                         77.8%; Pred. No. 7.5e-51;
                                9; Mismatches
  Matches 112; Conservative
                                                17; Indels
            1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
              1 MDFGLSLIFLVLVFKGVLCDVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTP 60
Db
```

```
61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRY-- 118
Qу
             61 EKRLEFVAAINSNGGSTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALYYCARHRG 120
Db
         119 --- DHYSG-SSDYWGQGTTVTVSS 138
Qy
                  | | : ||||||||
Db
         121 RDSSGYVGYAIDYWGQGTSVTVSS 144
RESULT 4
US-08-836-561-23
; Sequence 23, Application US/08836561
; Patent No. 6018032
  GENERAL INFORMATION:
    APPLICANT: KOIKE, Masamichi
    APPLICANT: FURUYA, Akiko
    APPLICANT: NAKAMURA, Kazuyasu
    APPLICANT: IIDA, Akihiro
    APPLICANT:
                ANAZAWA, Hideharu
    APPLICANT:
                HANAI, No. 6018032uo
    APPLICANT: TAKATSU, Kiyoshi
    TITLE OF INVENTION: Antibody Against Human Interleukin-5
    TITLE OF INVENTION: Receptor Alpha Chain
    NUMBER OF SEQUENCES: 106
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Pennie & Edmonds LLP
      STREET: 1155 Avenue of the Americas
      CITY: New York
      STATE: NY
      COUNTRY: USA
      ZIP: 10036
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 2.0
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/836,561
      FILING DATE: 09-MAY-1997
      CLASSIFICATION: 424
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: JP 232384/95
      FILING DATE: 11-SEP-1995
    ATTORNEY/AGENT INFORMATION:
      NAME: Lawrence, III, Stanton T
      REGISTRATION NUMBER: 25,736
      REFERENCE/DOCKET NUMBER: 7005-115-999
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 212-790-9090
      TELEFAX: 212-869-9741
      TELEX: 66141 PENNIE
   INFORMATION FOR SEQ ID NO: 23:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 140 amino acids
      TYPE: amino acid
```

STRANDEDNESS: single

```
TOPOLOGY: linear
    MOLECULE TYPE: protein
     FRAGMENT TYPE: internal
US-08-836-561-23
                        76.4%; Score 549; DB 3; Length 140;
  Query Match
  Best Local Similarity 74.3%; Pred. No. 1e-50;
  Matches 104; Conservative 16; Mismatches 18; Indels
                                                                       1;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGLSLIFLALILKGVQCEVQLVESGGDLVKPGGSLKLSCAASGFTFSDYGMAWIRQIS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
. Qy
             61 DKRPEWVAAISSGGSYIHFPDSLKGRFTVSRDNAKNTLYLEMSGLKSEDTAMYYCARRGF 120
         121 YSG--SSDYWGQGTTVTVSS 138
                  : ||||||||
             121 YGNYRAMDYWGQGTSVTVSS 140
RESULT 5
US-09-434-122-23
; Sequence 23, Application US/09434122
 Patent No. 6538111
    GENERAL INFORMATION:
        APPLICANT: KOIKE, Masamichi
                   FURUYA, Akiko
                  NAKAMURA, Kazuyasu
                   IIDA, Akihiro
                   ANAZAWA, Hideharu
                   HANAI, No. 6538111uo
                   TAKATSU, Kiyoshi
         TITLE OF INVENTION: Antibody Against Human Interleukin-5
                           Receptor Alpha Chain
        NUMBER OF SEQUENCES: 106
         CORRESPONDENCE ADDRESS:
             ADDRESSEE: Pennie & Edmonds LLP
             STREET: 1155 Avenue of the Americas
             CITY: New York
             STATE: NY
             COUNTRY: USA
             ZIP: 10036
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Diskette
             COMPUTER: IBM Compatible
             OPERATING SYSTEM: DOS
             SOFTWARE: FastSEQ Version 2.0
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/09/434,122
             FILING DATE: 05-No. 6538111-1999
         PRIOR APPLICATION DATA:
             APPLICATION NUMBER: 08/836,561
             FILING DATE: 09-MAY-1997
             APPLICATION NUMBER: JP 232384/95
             FILING DATE: 11-SEP-1995
```

```
ATTORNEY/AGENT INFORMATION:
             NAME: Lawrence, III, Stanton T
             REGISTRATION NUMBER: 25,736
             REFERENCE/DOCKET NUMBER: 7005-115-999
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: 212-790-9090
             TELEFAX: 212-869-9741
             TELEX: 66141 PENNIE
    INFORMATION FOR SEQ ID NO: 23:
        SEQUENCE CHARACTERISTICS:
             LENGTH: 140 amino acids
             TYPE: amino acid
             STRANDEDNESS: single
             TOPOLOGY: linear
        MOLECULE TYPE: protein
        FRAGMENT TYPE: internal
        SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-09-434-122-23
                         76.4%; Score 549; DB 4; Length 140;
 Query Match
                         74.3%; Pred. No. 1e-50;
 Best Local Similarity
 Matches 104; Conservative 16; Mismatches 18; Indels
                                                               2; Gaps
                                                                           1;
           1 \  \, \text{MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGF} \\ \text{TFSNYGMSWVRQNS} \quad 60
Qy
             1 MNFGLSLIFLALILKGVQCEVQLVESGGDLVKPGGSLKLSCAASGFTFSDYGMAWIRQIS 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              61 DKRPEWVAAISSGGSYIHFPDSLKGRFTVSRDNAKNTLYLEMSGLKSEDTAMYYCARRGF 120
Db
         121 YSG--SSDYWGQGTTVTVSS 138
Qу
                  : ||||||:||:||
         121 YGNYRAMDYWGQGTSVTVSS 140
RESULT 6
PCT-US94-07659-2
; Sequence 2, Application PC/TUS9407659
   GENERAL INFORMATION:
    APPLICANT: Young, Peter
    APPLICANT: Gross, Mitchell
    APPLICANT: Jonak, Zdenka L.
    APPLICANT: Theisen, Timothy
    APPLICANT: Hurle, Mark
    APPLICANT: Jackson, Jeffrey R.
    TITLE OF INVENTION: Recombinant and Humanized Il-1 beta
TITLE OF INVENTION: Antibodies for Treatment of Il-1 Mediated Inflammatory
    TITLE OF INVENTION: Disorders in Man
    NUMBER OF SEQUENCES: 21
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: SmithKline Beecham Corporation - Corp.
      ADDRESSEE: Intellectual Property
       STREET: 709 Swedeland Road
      CITY: King of Prussia
      STATE: PA
      COUNTRY: USA
```

```
ZIP: 19406-2799
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
;
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: PCT/US94/07659
      FILING DATE:
      CLASSIFICATION:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/090,534
      FILING DATE: 09-JUL-1993
    ATTORNEY/AGENT INFORMATION:
      NAME: Sutton, Jeffrey A.
      REGISTRATION NUMBER: 34,028
      REFERENCE/DOCKET NUMBER: P50171-1
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (610) 270-5024
      TELEFAX: (610) 270-5090
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 247 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
PCT-US94-07659-2
                       76.4%; Score 549; DB 5; Length 247;
 Query Match
                       78.3%; Pred. No. 2.1e-50;
 Best Local Similarity
                              7; Mismatches 23; Indels
 Matches 108; Conservative
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGLRLIFLVLTLKGVKCEVHLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 EKRLDWVAYISSGGGGTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYHCARGGV 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
                121 RRGYFDVWGAGTTVTVSS 138
RESULT 7
US-08-579-378A-20
; Sequence 20, Application US/08579378A
; Patent No. 6210671
  GENERAL INFORMATION:
    APPLICANT: Co, Man Sung
    TITLE OF INVENTION: Humanized Antibodies Reactive with
    TITLE OF INVENTION: L-Selectin
    NUMBER OF SEQUENCES: 20
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Townsend and Townsend and Crew
      STREET: One MarketPlaza, Steuart Tower, Suite 2000
```

```
CITY: San Francisco
      STATE: California
      COUNTRY: USA
      ZIP: 94105
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
;
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/579,378A
      FILING DATE: 27-DEC-1995
      CLASSIFICATION: 424
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/160,074
      FILING DATE: 30-NOV-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/983,946
      FILING DATE: 01-DEC-1992
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: EP 95112895.8
      FILING DATE: 17-AUG-1995
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: EP 95114696.8
      FILING DATE: 19-SEP-1995
    ATTORNEY/AGENT INFORMATION:
      NAME: Liebescheutz, Joe O.
      REGISTRATION NUMBER: 37,505
      REFERENCE/DOCKET NUMBER: 11823-002220
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-326-2400
      TELEFAX: 415-326-2422
  INFORMATION FOR SEQ ID NO: 20:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 135 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-579-378A-20
                       75.9%; Score 545.5; DB 3;
                                                  Length 135;
 Query Match
 Best Local Similarity 79.0%; Pred. No. 2.3e-50;
                                                                       2;
                              9; Mismatches 17; Indels
                                                           3; Gaps
 Matches 109; Conservative
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGSSLIFLVLVLKGVQCEVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              61 GKGLEWVASI-STGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAR--D 117
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
             1 | 111111 | 1111
         118 YDGYFDYWGQGTLVTVSS 135
Db
```

```
RESULT 8
US-08-976-183A-33
; Sequence 33, Application US/08976183A
; Patent No. 6307026
  GENERAL INFORMATION:
    APPLICANT: King, David J.
    APPLICANT: Adair, John R.
    APPLICANT: Owens, Raymond J.
    TITLE OF INVENTION: HUMANISED ANTIBODIES DIRECTED AGAINST A33
    TITLE OF INVENTION: ANTIGEN
    NUMBER OF SEQUENCES: 55
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: FOLEY & LARDNER
       STREET: 3000 K. Street, N.W., Suite 500
      CITY: Washington, D.C.
      COUNTRY: USA
       ZIP: 20007
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
       COMPUTER: IBM PC compatible
       OPERATING SYSTEM: PC-DOS/MS-DOS
    SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/976,183A
      FILING DATE:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/595,848
      FILING DATE: 02-FEB-1996
      APPLICATION NUMBER: PCT/GB93/02529
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: GB 9225853.2
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 9315249.4
      FILING DATE: 22-JUL-1993
    ATTORNEY/AGENT INFORMATION:
      NAME: Bernhard D. Saxe
       REGISTRATION NUMBER: 28,665
      REFERENCE/DOCKET NUMBER: 40283/151/CARA
    TELECOMMUNICATION INFORMATION:
       TELEPHONE: (202) 672-5300
       TELEFAX: (202) 672-5399
       TELEX: 904136
  INFORMATION FOR SEQ ID NO: 33:
    SEQUENCE CHARACTERISTICS:
       LENGTH: 136 amino acids
       TYPE: amino acid
       STRANDEDNESS: single
       TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-976-183A-33
  Query Match 75.2%; Score 541; DB 3; Length 136; Best Local Similarity 75.5%; Pred. No. 7.1e-50;
  Matches 108; Conservative 10; Mismatches 13; Indels 12; Gaps
                                                                             2;
```

```
1 \hspace{0.1cm} \texttt{MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS} \hspace{0.2cm} \textbf{60} \\
Qy
             1 MNFGLSLIFLVLILKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYC---- 115
QУ
             61 EKRLEWVATISSGGSYTYYLDSVKGRFTISRDSARNTLYLQMSSLRSEDTALYYCAPTTV 120
Db
         116 VRYDHYSGSSDYWGQGTTVTVSS 138
Qу
             1:
                       121 VPF-----AYWGQGTLVTVSA 136
Db
RESULT 9
US-08-976-183A-31
; Sequence 31, Application US/08976183A
; Patent No. 6307026
  GENERAL INFORMATION:
    APPLICANT: King, David J.
    APPLICANT: Adair, John R.
    APPLICANT: Owens, Raymond J.
    TITLE OF INVENTION: HUMANISED ANTIBODIES DIRECTED AGAINST A33
    TITLE OF INVENTION: ANTIGEN
    NUMBER OF SEQUENCES: 55
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: FOLEY & LARDNER
      STREET: 3000 K. Street, N.W., Suite 500
      CITY: Washington, D.C.
      COUNTRY: USA
      ZIP: 20007
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/976,183A
      FILING DATE:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/595,848
      FILING DATE: 02-FEB-1996
      APPLICATION NUMBER: PCT/GB93/02529
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: GB 9225853.2
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 9315249.4
      FILING DATE: 22-JUL-1993
    ATTORNEY/AGENT INFORMATION:
      NAME: Bernhard D. Saxe
      REGISTRATION NUMBER: 28,665
      REFERENCE/DOCKET NUMBER: 40283/151/CARA
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: (202) 672-5300
      TELEFAX: (202) 672-5399
      TELEX: 904136
```

```
INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 136 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-976-183A-31
                       75.1%; Score 540; DB 3; Length 136;
 Query Match
                       74.8%; Pred. No. 9.1e-50;
 Best Local Similarity
 Matches 107; Conservative 11; Mismatches
                                            13; Indels
                                                                       2;
                                                          12; Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MNFGLSLVFLVLILKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYC---- 115
Qу
             61 EKRLEWVATISSGGSYTYYLDSVKGRFTISRDSARNTLYLOMSSLRSEDTALYYCAPTTV 120
Db
         116 VRYDHYSGSSDYWGQGTTVTVSS 138
Qy
                      | :
         121 VPF-----AYWGQGTLVTVSA 136
Db
RESULT 10
US-08-976-183A-32
; Sequence 32, Application US/08976183A
; Patent No. 6307026
  GENERAL INFORMATION:
    APPLICANT: King, David J.
    APPLICANT: Adair, John R.
    APPLICANT: Owens, Raymond J.
    TITLE OF INVENTION: HUMANISED ANTIBODIES DIRECTED AGAINST A33
    TITLE OF INVENTION: ANTIGEN
    NUMBER OF SEQUENCES: 55
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: FOLEY & LARDNER
      STREET: 3000 K. Street, N.W., Suite 500
      CITY: Washington, D.C.
      COUNTRY: USA
      ZIP: 20007
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/976,183A
      FILING DATE:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/595,848
      FILING DATE: 02-FEB-1996
      APPLICATION NUMBER: PCT/GB93/02529
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
```

```
APPLICATION NUMBER: GB 9225853.2
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 9315249.4
      FILING DATE: 22-JUL-1993
    ATTORNEY/AGENT INFORMATION:
      NAME: Bernhard D. Saxe
      REGISTRATION NUMBER: 28,665
      REFERENCE/DOCKET NUMBER: 40283/151/CARA
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (202) 672-5300
      TELEFAX: (202) 672-5399
      TELEX: 904136
  INFORMATION FOR SEQ ID NO: 32:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 136 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-976-183A-32
 Query Match
                       74.7%; Score 537; DB 3; Length 136;
 Best Local Similarity 74.8%; Pred. No. 1.9e-49;
 Matches 107; Conservative 10; Mismatches 14; Indels
                                                          12; Gaps
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy .
            1 MNFGFSLIFLVLILKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYC---- 115
Qу
             61 EKRLEWVATISSGGSYTYYLDSVKGRFTISRDSARNTLYLQMSSLRSEDTALYYCAPTTV 120
Db
         116 VRYDHYSGSSDYWGQGTTVTVSS 138
Qу
            | :
                      121 VPF-----AYWGQGTLVTVSA 136
Db ·
RESULT 11
US-08-976-183A-34
; Sequence 34, Application US/08976183A
; Patent No. 6307026
  GENERAL INFORMATION:
    APPLICANT: King, David J.
    APPLICANT: Adair, John R.
    APPLICANT: Owens, Raymond J.
    TITLE OF INVENTION: HUMANISED ANTIBODIES DIRECTED AGAINST A33
    TITLE OF INVENTION: ANTIGEN
    NUMBER OF SEQUENCES: 55
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: FOLEY & LARDNER
      STREET: 3000 K. Street, N.W., Suite 500
      CITY: Washington, D.C.
      COUNTRY: USA
      ZIP: 20007
    COMPUTER READABLE FORM:
```

```
MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/976,183A
      FILING DATE:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/595,848
      FILING DATE: 02-FEB-1996
      APPLICATION NUMBER: PCT/GB93/02529
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: GB 9225853.2
      FILING DATE: 10-DEC-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 9315249.4
      FILING DATE: 22-JUL-1993
    ATTORNEY/AGENT INFORMATION:
      NAME: Bernhard D. Saxe
      REGISTRATION NUMBER: 28,665
      REFERENCE/DOCKET NUMBER: 40283/151/CARA
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (202) 672-5300
      TELEFAX: (202) 672-5399
      TELEX: 904136
  INFORMATION FOR SEQ ID NO: 34:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 136 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-976-183A-34
 Query Match
                       74.5%; Score 536; DB 3; Length 136;
 Best Local Similarity 74.1%; Pred. No. 2.4e-49;
 Matches 106; Conservative 11; Mismatches 14; Indels
                                                          12; Gaps
                                                                      2;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            Db
           1 MNFGFSLVFLVLILKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYC---- 115
Qу
             Db
          61 EKRLEWVATISSGGSYTYYLDSVKGRFTISRDSARNTLYLQMSSLRSEDTALYYCAPTTV 120
         116 VRYDHYSGSSDYWGQGTTVTVSS 138
Qу
            |:
                      Db
         121 VPF-----AYWGQGTLVTVSA 136
RESULT 12
US-08-253-877C-57
```

; Sequence 57, Application US/08253877C

; Patent No. 5773001 ; GENERAL INFORMATION:

```
APPLICANT: Hamann, Philip R.
    APPLICANT: Hinman, Lois
    APPLICANT:
               Hollander, Irwin
    APPLICANT:
               Holcomb, Ryan
               Hallett, William
    APPLICANT:
    APPLICANT: Tsou, Hwei-Ru
    APPLICANT: Weiss, Martin J.
    TITLE OF INVENTION: Conjugates of Methyltrithio Antitumor
    TITLE OF INVENTION: Agents and Intermediates for Their Synthesis
    NUMBER OF SEQUENCES: 73
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: American Cyanamid Company
      STREET: One Cyanamid Plaza
      CITY: Wayne
      STATE: New Jersey
      COUNTRY: U.S.A.
      ZIP: 07470-8426
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/253,877C
      FILING DATE: 03-JUN-1994
      CLASSIFICATION: 424
    ATTORNEY/AGENT INFORMATION:
      NAME: Barnhard, Elizabeth M.
      REGISTRATION NUMBER: 31,088
      REFERENCE/DOCKET NUMBER: 32,368
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 201-831-3246
      TELEFAX: 201-831-3305
  INFORMATION FOR SEQ ID NO: 57:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 136 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-253-877C-57
                       74.4%; Score 535; DB 1; Length 136;
 Query Match
 Best Local Similarity
                       74.1%; Pred. No. 3.1e-49;
 Matches 106; Conservative 11; Mismatches 14; Indels
                                                                       2;
                                                           12; Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLVFLVLILKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYC---- 115
Qу
             61 EKRLEWVATISSGGSYTYYLDSVKGRFTISRDSPRNTLYLQMSSLRSEDTALYYCAPTTV 120
Db
         116 VRYDHYSGSSDYWGQGTTVTVSS 138
Qу
             | :
                      ||||||
Db
         121 VPF-----AYWGQGTLVTVSA 136
```

```
RESULT 13
US-08-452-164A-57
; Sequence 57, Application US/08452164A
; Patent No. 5877296
  GENERAL INFORMATION:
    APPLICANT: Hamann, Philip R.
    APPLICANT: Hinman, Lois
    APPLICANT: Hollander, Irwin
    APPLICANT: Holcomb, Ryan
    APPLICANT: Hallett, William .
    APPLICANT: Tsou, Hwei-Ru
    APPLICANT: Weiss, Martin J.
    TITLE OF INVENTION: Conjugates of Methyltrithio Antitumor
    TITLE OF INVENTION: Agents and Intermediates for Their Synthesis
    NUMBER OF SEQUENCES: 73
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: American Home Products Corporation
      STREET: One Campus Drive
      CITY: Parsippany
;
      STATE: New Jersey
      COUNTRY: U.S.A.
      ZIP: 07054
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/452,164A
      FILING DATE: 26-MAY-1995
      CLASSIFICATION: 530
    ATTORNEY/AGENT INFORMATION:
      NAME: Barnhard, Elizabeth M.
      REGISTRATION NUMBER: 31,088
      REFERENCE/DOCKET NUMBER: 32,368-04
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 201-683-2158
      TELEFAX: 201-683-4117
  INFORMATION FOR SEQ ID NO: 57:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 136 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-452-164A-57
                        74.4%; Score 535; DB 2; Length 136;
 Query Match
 Best Local Similarity
                       74.1%; Pred. No. 3.1e-49;
 Matches 106; Conservative
                            11; Mismatches 14; Indels 12; Gaps
                                                                       2;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGLSLVFLVLILKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYC---- 115
Qy
```

```
61 EKRLEWVATISSGGSYTYYLDSVKGRFTISRDSPRNTLYLQMSSLRSEDTALYYCAPTTV 120
Db
         116 VRYDHYSGSSDYWGQGTTVTVSS 138
QУ
            |:
                     121 VPF-----AYWGQGTLVTVSA 136
Db
RESULT 14
US-08-053-171-7
; Sequence 7, Application US/08053171
; Patent No. 5562903
  GENERAL INFORMATION:
    APPLICANT: Co, Loibner
    TITLE OF INVENTION: Antibody Derivatives
    NUMBER OF SEQUENCES: 32
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Townsend and Townsend Khourie and Crew
      STREET: 379 Lytton Avenue
      CITY: Palo Alto
      STATE: California
      COUNTRY: US
      ZIP: 94301
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/053,171
      FILING DATE: 22-APR-1993
      CLASSIFICATION: 424
    ATTORNEY/AGENT INFORMATION:
      NAME: Smith, Willaim M
      REGISTRATION NUMBER: 30,223
      REFERENCE/DOCKET NUMBER: 11823-54-1
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (415) 326-2400
      TELEFAX: (415) 326-2422
  INFORMATION FOR SEQ ID NO: 7:
    SEOUENCE CHARACTERISTICS:
      LENGTH: 138 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-053-171-7
                       74.4%; Score 535; DB 1; Length 138;
 Query Match
 Best Local Similarity 75.4%; Pred. No. 3.1e-49;
 Matches 104; Conservative 12; Mismatches 22; Indels
                                                           0; Gaps
                                                                     0;
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            1 MNLGLSLIFLVLVLKGVQCEVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qy
            61 EKRLEWVAYISNGGGSSHYVDSVKGRFTISRDNAKNTLYLQMSRLRSEDTAMYHCARGMD 120
Db
```

```
121 YSGSSDYWGQGTTVTVSS 138
Qу
                  121 YGAWFAYWGQGTLVTVSA 138
Db
RESULT 15
US-08-053-171-11
; Sequence 11, Application US/08053171
; Patent No. 5562903
  GENERAL INFORMATION:
    APPLICANT: Co, Loibner
    TITLE OF INVENTION: Antibody Derivatives
    NUMBER OF SEQUENCES: 32
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Townsend and Townsend Khourie and Crew
      STREET: 379 Lytton Avenue
      CITY: Palo Alto
      STATE: California
      COUNTRY: US
      ZIP: 94301
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/053,171
      FILING DATE: 22-APR-1993
      CLASSIFICATION: 424
    ATTORNEY/AGENT INFORMATION:
      NAME: Smith, Willaim M
      REGISTRATION NUMBER: 30,223
      REFERENCE/DOCKET NUMBER: 11823-54-1
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (415) 326-2400
      TELEFAX: (415) 326-2422
   INFORMATION FOR SEQ ID NO: 11:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 138 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-053-171-11
                        74.4%; Score 535; DB 1; Length 138; 75.4%; Pred. No. 3.1e-49;
  Query Match
  Best Local Similarity
 Matches 104; Conservative
                             12; Mismatches
                                              22;
                                                  Indels
                                                                Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNLGLSLIFLVLVLKGVQCEVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
```

61 EKRLEWVAYISNGGGSSHYVDSVKGRFTISRDNAKNTLYLQMSRLRSEDTAMYHCARGMD 120

Db

Search completed: December 13, 2004, 19:19:41

Job time : 29.6222 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 13, 2004, 19:04:43; Search time 24.5333 Seconds

(without alignments)

541.219 Million cell updates/sec

Title: US-10-010-942B-4

Perfect score: 719

Sequence: 1 MNFGLSLIFLVLVLKGVQCE.....DHYSGSSDYWGQGTTVTVSS 138

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: PIR 79:\*

1: pir1:\*

2: pir2:\*

3: pir3:\*

4: pir4:\*

O.

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

			¥				•
Re	sult		Query				
	No.	Score	Match	Length I	OΒ	ID	Description
_							
	1	573	79.7	138	2	S09258	Ig heavy chain V r
	2	569	79.1	152	2	B26471	Ig heavy chain pre
	3	559.5	77.8	139	2	S38808	Ig heavy chain - m
	4	544	75.7	142	2	C34903	Ig heavy chain pre
	5	521.5	72.5	140	2	S70442	Ig heavy chain pre
	6	517	71.9	140	2	S31686	Ig heavy chain V r
	7	516	71.8	160	2	S05271	. Ig heavy chain pre
	8	514	71.5	134	2	S31699	Ig heavy chain V r
	9	513	71.3	140	2	S31588	Ig heavy chain V r
	10	512	71.2	117	1	HVMS84	Ig heavy chain pre
	11	510	70.9	117	1	HVMS34	Ig heavy chain pre
	12	508	70.7	136	2	S31615	hypothetical prote
	13	504	70.1	140	2	S22657	Ig heavy chain pre

						•
14	502.5	69.9	136	1	G1MS21	Ig heavy chain pre
15	.502	69.8	138	2	S31666	Ig heavy chain W r
16	501	69.7	117	1	HVMS39	Ig heavy chain pre
17	495	68.8	135	2	S31598	Ig heavy chain V r
18	493	68.6	134	2	S31679	Ig heavy chain V r
19	492.5	68.5	141	2	S31669	Ig heavy chain V r
20	492	68.4	117	1	HVMSRF	/ Ig heavy chain pre
21	492	68.4	139	2	I37781	Ig variable region
22	490	68.2	122	2	E27888	Ig heavy chain V r
23	487.5	67.8	119	2	F27888	Ig heavy chain V r
24	485.5	67.5	136	2	S31587	Ig heavy chain V r
25	484.5	67.4	151	2	A60943	Ig heavy chain pre
26	484	67.3	117	1	HVMS57	Ig heavy chain pre
27	484	67.3	140	2	A30532	Ig heavy chain pre
28	483	67.2	120	2	S55536	Ig heavy chain V r
29	481.5	67.0	147	2	I37780	Ig variable region
30	480.5	66.8	118	2	PH0096	Ig heavy chain V r
31	480.5	66.8	121	2	S55540	Ig heavy chain V r
32	480.5	66.8	254	2	B31790	Ig heavy.chain V r
33	479	66.6	120	2	S55538	Ig heavy chain V r
34	479	66.6	120	2	\$55539	Ig heavy chain V r
35	477.5	66.4	121	2	H27888	Ig heavy chain V r
36	477.5	66.4	137	2	S31701	Ig heavy chain V r
37	477.5	66.4	139	2	S31674	Ig heavy chain V r
38	476.5	66.3	137	2	S78054	Ig heavy chain pre
39	476	66.2	120	2	S55537	Ig heavy chain V r
40	473.5	65.9	118	, 2	PH0097	Ig heavy chain V r
41	472	65.6	132	2	S31603	Ig heavy chain V r
42	471	65.5	130	2	PL0098	Ig heavy chain pre
43	469	65.2	118	2	S20641	Ig heavy chain V r
44	467.5	65.0	135	2	137778	Ig variable region
45	467.5	65.0	145	2	S11239	Ig heavy chain V r

## ALIGNMENTS

```
Ig heavy chain V region precursor - mouse (fragment)
C; Species: Mus musculus (house mouse)
C;Date: 29-Jan-1993 #sequence revision 29-Jan-1993 #text change 23-Jul-1999
C; Accession: S09258
R; Hamada, H.; Maezawa, K.; Tsuruo, T.
Nucleic Acids Res. 18, 1900, 1990
A; Title: Nucleotide sequences of the wariable regions of a mouse monoclonal
antibody MRK16.
A; Reference number: S09258; MUID: 90245594; PMID: 2110659
A; Accession: S09258
A; Molecule type: DNA
A; Residues: 1-138 <HAM>
A;Cross-references: EMBL:X51719; NID:g53207; PIDN:CAA36012.1; PID:g297545
C; Genetics:
A; Introns: 16/1
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>
```

RESULT 1 S09258

```
Query Match
                        79.7%; Score 573; DB 2; Length 138;
 Best Local Similarity
                        80.4%; Pred. No. 5.8e-43;
 Matches 111; Conservative
                              8; Mismatches
                                             19; Indels
                                                                Gaps
                                                                       0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLILKGVQCEVILVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 EKRLEWVATISSGGGNTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARYYR 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
                   1
         121 YEAWFASWGQGTLVTVSA 138
Db
RESULT 2
B26471
Ig heavy chain precursor V region (MAK33) - mouse
C; Species: Mus musculus (house mouse)
C;Date: 05-Jun-1988 #sequence revision 05-Jun-1988 #text change 23-Jul-1999
C; Accession: B26471; S70410
R; Buckel, P.; Hubner-Parajsz, C.; Mattes, R.; Lenz, H.; Haug, H.; Beaucamp, K.
Gene 51, 13-19, 1987
A; Title: Cloning and nucleotide sequence of heavy- and light-chain cDNAs from a
creatine-kinase-specific monoclonal antibody.
A; Reference number: A91572; MUID: 87248058; PMID: 3110009
A; Accession: B26471
A; Molecule type: mRNA
A; Residues: 1-152 < BUC>
A; Cross-references: GB:M16163; NID:q195405; PIDN:AAA38292.1; PID:q195406
R; Lebecque, S.G.; Gearhart, P.J.
J. Exp. Med. 172, 1717-1727, 1990
A; Title: Boundaries of somatic mutation in rearranged immunoglobulin genes: 5'
boundary is near the promoter, and 3' boundary is about 1 kb from V(D)J gene.
A; Reference number: S70410; MUID: 91079775; PMID: 2258702
A; Accession: S70410
A; Status: translation not shown
A; Molecule type: DNA
A; Residues: 1-19 <LEB>
A;Cross-references: EMBL:X53776; NID:g52475; PIDN:CAA37792.1; PID:g52476
C; Genetics:
A; Introns: 16/1
C; Superfamily: 'immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-152/Product: Iq heavy chain V region MAK33 #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                        79.1%; Score 569; DB 2; Length 152;
  Best Local Similarity
                        78.2%; Pred. No. 1.4e-42;
 Matches 111; Conservative
                            10; Mismatches
                                             17;
                                                  Indels
                                                                Gaps
                                                                       1;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
```

```
Db
           1 MNFGLSLIFLVLVLKGVQCEVQGVESGGGLVKPGGSLKLSCAASGFTFSDYYMYWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
Qу
             61 EKRLEWVATISDGGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCARDKA 120
Db
         118 -YDHYSGSSDYWGQGTTVTVSS 138
Qv
              Db
         121 YYGNYGDAMDYWGQGTSVTVSS 142
RESULT 3
S38808
Ig heavy chain - mouse
C; Species: Mus musculus (house mouse)
C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 21-Jan-2000
C; Accession: S38808
R; Sequeira, A.; Avrameas, S.; Jouvin-Marche, E.
Immunogenetics 36, 15-21, 1992
A; Title: Molecular characterization of the variable regions of a mouse
polyreactive IgG2b antibody with rheumatoid factor activity.
A; Reference number: S38807; MUID: 92267566; PMID: 1587549
A; Accession: S38808
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-139 <SEQ>
A; Cross-references: EMBL: X53400
A; Note: the authors translated the codon GAG for residue 117 as Lys
A; Note: the sequence of residues 134-139 and the corresponding nucleotide
sequence are not shown in this paper
C; Superfamily: immunoglobulin V region; immunoglobulin homology
F;34-116/Domain: immunoglobulin homology <IMM>
 Query Match
                       77.8%;
                               Score 559.5; DB 2;
                                                  Length 139;
 Best Local Similarity
                       79.3%;
                               Pred. No. 8.7e-42;
 Matches 111; Conservative
                              8; Mismatches
                                                  Indels
                                                                      2;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MNFGFSLIFLVLVLKGVQCEVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 EKRLEWVASI-SRGGTTYYPDSVKGRFTISRDNARNNLYLQMSSLRSEDTAMYYCAREGI 119
Db
         121 YSG---SSDYWGQGTTVTV 136
Qy.....
                                               Db
         120 YYGYALYGMDYWGQGTSVTV 139
RESULT 4
C34903
Ig heavy chain precursor V region (5-27) - mouse
C; Species: Mus musculus (house mouse)
C; Date: 27-Jul-1990 #sequence revision 27-Jul-1990 #text change 16-Aug-1996
C; Accession: C34903
R; Bedzyk, W.D.; Herron, J.N.; Edmundson, A.B.; Voss Jr., E.W.
```

```
J. Biol. Chem. 265, 133-138, 1990
A; Title: Active site structure and antigen binding properties of idiotypically
cross-reactive anti-fluorescein monoclonal antibodies.
A; Reference number: A34903; MUID: 90094387; PMID: 2104617
A; Accession: C34903
A; Status: preliminary; not compared with conceptual translation
A; Molecule type: mRNA
A; Residues: 1-142 <BED>
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;34-119/Domain: immunoglobulin homology <IMM>
                        75.7%;
 Query Match
                               Score 544; DB 2; Length 142;
 Best Local Similarity
                               Pred. No. 2e-40;
                        76.1%;
 Matches 108; Conservative
                               9; Mismatches
                                              21; Indels
                                                             4; Gaps
                                                                        2:
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGFSLIFLVLVLKGVQCEVKWVESGGGLVSPGGSLKLSCAASGFTFSTYAMSWVRQTP 60
Db
          61 DKRLEWVASI--RSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRY 118
Qу
             : | | | | | | | |
                      61 EKRLEWVASFGNKPTGGRTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARG 120
Db
         119 DHYSGS--SDYWGQGTTVTVSS 138
Qу
              : | |
                      121 GYYYGGYWFAYWGQGTLVTVSA 142
Dh
RESULT 5
S70442
Ig heavy chain precursor V region (mu) - human (fragment)
C; Species: Homo sapiens (man)
C; Date: 24-Jul-1998 #sequence revision 24-Jul-1998 #text change 09-Jul-2004
C; Accession: S70442
R; Cuisinier, A.M.; Fumoux, F.; Fougereau, M.; Tonnelle, C.
Mol. Immunol. 29, 1363-1373, 1992
A; Title: IgM kappa/lambda EBV human B cell clone: an early step of
differentiation of fetal B cells or a distinct B lineage?
A; Reference number: S70442; MUID: 93024508; PMID: 1383695
A; Accession: S70442
A; Status: not compared with conceptual translation
A; Molecule type: mRNA
A; Residues: 1-140 <CUI>
A; Cross-references: UNIPROT: Q8WUK1
C; Superfamily; immunoglobulin V region; immunoglobulin homology
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                        72.5%; Score 521.5; DB 2;
                                                   Length 140;
 Best Local Similarity
                        71.4%; Pred. No. 1.8e-38;
 Matches 100; Conservative 18; Mismatches
                                               19;
                                                   Indels
                                                             3; Gaps
                                                                        2;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MEFGLSWVFLVALLRGVQCQVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
```

```
61 GKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR-DH 119
Db
         121 YSGSS--DYWGQGTTVTVSS 138
Qу
              120 IVGATYFDYWGQGTLVTVSS 139
Db
RESULT 6
S31686
Ig heavy chain V region - human (fragment)
C; Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence revision 10-Nov-1995 #text change 23-Jul-1999
C; Accession: S31686
R; Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A; Description: Mechanisms that generate human immunoglobulin diversity operate
from the 8th week of gestation in feral liver.
A; Reference number: S31585
A; Accession: S31686
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-140 <CUI>
A; Cross-references: EMBL: Z14205; NID: g30969; PIDN: CAA78574.1; PID: g30970
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                        71.9%; Score 517; DB 2; Length 140;
                       70.7%; Pred. No. 4.4e-38;
 Best Local Similarity
           99; Conservative
                            17; Mismatches
                                              22; Indels
                                                            2; Gaps
                                                                       1;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MEFGLSWLSLVAILKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
                        61 GKGLEWVSAISGSGGSTYYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKCPF 120
Db
         121 YSGSS--DYWGQGTTVTVSS 138
Qу
              | \cdot |
                   Db
         121 AGGSPSFDYWGQGTLVTVSS 140
RESULT 7
                  S05271
Ig heavy chain precursor - human (fragment)
C; Species: Homo sapiens (man)
C; Date: 30-Jun-1992 #sequence revision 30-Jun-1992 #text change 09-Jul-2004
C; Accession: S05271; S04602
R; Kishimoto, T.
submitted to the EMBL Data Library, March 1989
A; Reference number: S05270
A; Accession: S05271
A; Molecule type: mRNA
A; Residues: 1-160 <KIS1>
```

```
A; Cross-references: UNIPROT: Q96BB9; EMBL: X14584
R; Kishimoto, T.; Okajima, H.; Okumoto, T.; Taniquchi, M.
Nucleic Acids Res. 17, 4385, 1989
A; Title: Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-
chains of a human monoclonal antibody with broad reactivity to malignant tumor
A; Reference number: S04601; MUID: 89296497; PMID: 2500644
A; Accession: S04602
A; Molecule type: mRNA
A; Residues: 1-144 <KIS2>
A; Cross-references: EMBL: X14584
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-160/Product: Ig heavy chain (fragment) #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                         71.8%; Score 516; DB 2; Length 160;
                         68.1%; Pred. No. 6.2e-38;
 Best Local Similarity
 Matches
          98; Conservative
                              18; Mismatches
                                                 22;
                                                     Indels
                                                                   Gaps
                                                                           1;
Qу
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
             1 MEFGLSWLFLVAILKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
Qу
              | | | | | | : : |
                          61 GKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAVV 120
Db
         118 ---YDHYSGSSDYWGQGTTVTVSS 138
Qу
                  : |
                        1 1 1 1 1 1 1 1 1 1 1 1
         121 RGVISYYYYGMDVWGQGTTVTVSS 144
Db
RESULT 8
S31699
Ig heavy chain V region - human (fragment)
C; Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence revision 10-Nov-1995 #text change 23-Jul-1999
C; Accession: S31699
R; Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A; Description: Mechanisms that generate human immunoglobulin diversity operate
from the 8th week of gestation in feral liver.
A; Reference number: S31585
A; Accession: S31699
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-134 <CUI>
A;Cross-references: EMBL:Z14201; NID:q30961; PIDN:CAA78570.1; PID:q30962
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                         71.5%; Score 514; DB 2; Length 134;
                         71.0%; Pred. No. 7.7e-38;
 Best Local Similarity
 Matches 98; Conservative
                              16; Mismatches
                                                                           1;
                                                 20; Indels
                                                                   Gaps ·
```

```
1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
            1 MEFGLSWLFLVAILKGVQCEVQLLESGGGLVHPGGSLRLSCAASGFTFSSYAMSWVRQAP 60
Db
         61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 GKGLEWVSAISGSGGSTYYSDSVKGRLTISRDNSKNTLYLOMNSLRAEDTAVYYCARW-- 118
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
                 Db
        119 -- RDLDYWGQGTLVTVSS 134
RESULT 9
S31588
Ig heavy chain V region - human (fragment)
C; Species: Homo sapiens (man)
C; Date: 22-Nov-1993 #sequence revision 10-Nov-1995 #text change 23-Jul-1999
C; Accession: S31588
R; Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A; Description: Mechanisms that generate human immunoglobulin diversity operate
from the 8th week of gestation in feral liver.
A; Reference number: $31585
A; Accession: S31588
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-140 <CUI>
A; Cross-references: EMBL: Z14200; NID: q30957; PIDN: CAA78569.1; PID: q30958
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                       71.3%;
                              Score 513; DB 2; Length 140;
 Best Local Similarity
                       69.3%; Pred. No. 9.8e-38;
          97; Conservative 20; Mismatches
                                            21;
                                                                     1;
                                                          2;
                                                 Indels
                                                             Gaps
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            1 MEFGLSWLFLVAILRGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
                        Db
          61 GKGLEWVSAISGSGGSTYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCAKDHD 120
         121 YSG--SSDYWGOGTTVTVSS 138
Qy
            Db
         121 YSNYIYFDYWGOGTLVTVSS 140
RESULT 10
HVMS84
Ig heavy chain precursor V region (5-84) - mouse
C; Species: Mus musculus (house mouse)
C; Date: 30-Jun-1990 #sequence revision 30-Jun-1990 #text change 09-Jul-2004
C; Accession: JT0505
```

```
R; Levy, N.S.; Malipiero, U.V.; Lebecque, S.G.; Gearhart, P.J.
 J. Exp. Med. 169, 2007-2019, 1989
A; Title: Early onset of somatic mutation in immunoglobulin VH genes during the
primary immune response.
A; Reference number: JT0501; MUID: 89279149; PMID: 2499654
A; Accession: JT0505
A; Status: translation not shown
A; Molecule type: mRNA
A; Residues: 1-117 <LEV>
A; Cross-references: UNIPROT: P18525
A; Experimental source: strain BALB/cJ
A; Note: this sequence belongs to the VH7183 subfamily
 C; Superfamily: immunoglobulin V region; immunoglobulin homology
 C; Keywords: heterotetramer; immunoglobulin
 F;1-19/Domain: signal sequence #status predicted <SIG>
 F;20-117/Product: Ig heavy chain V region (5-84) #status predicted <MAT>
 F;34-117/Domain: immunoglobulin homology <IMM>
 F;41-115/Disulfide bonds: #status predicted
  Query Match
                          71.2%; Score 512; DB 1; Length 117;
                          84.6%; Pred. No. 1e-37;
  Best Local Similarity
            99; Conservative
                                6; Mismatches 12; Indels
                                                                0; Gaps
                                                                           0;
            1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
 Qу
              1 MNFGLSLIFLVLVLKGVLCEVKLVESGGGLVQPGGSLKLSCAASGFTFSSYTMSWVRQTP 60
 Db
           61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR 117
 Qу
              61 EKRLEWVAYISNGGGSTYYPDTVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCAR 117
 Db
 RESULT 11
 HVMS34
 Ig heavy chain precursor V region (345) - mouse
 C; Species: Mus musculus (house mouse)
 C; Date: 30-Jun-1990 #sequence revision 30-Jun-1990 #text change 09-Jul-2004
 C; Accession: JT0502
 R; Levy, N.S.; Malipiero, U.V.; Lebecque, S.G.; Gearhart, P.J.
 J. Exp. Med. 169, 2007-2019, 1989
 A; Title: Early onset of somatic mutation in immunoglobulin VH genes during the
 primary immune response.
 A; Reference number: JT0501; MUID: 89279149; PMID: 2499654
 A; Accession: JT0502
 A; Status: translation not shown
A; Molecule type: mRNA
 A; Residues: 1-117 <LEV>
 A; Cross-references: UNIPROT: P18526
 A; Experimental source: strain BALB/cJ
 A; Note: this sequence belongs to the VH7183 subfamily
 C; Superfamily: immunoglobulin V region; immunoglobulin homology
 C; Keywords: heterotetramer; immunoglobulin
 F;1-19/Domain: signal sequence #status predicted <SIG>
 F;20-117/Product: Ig heavy chain V region (345) #status predicted <MAT>
 F;34-117/Domain: immunoglobulin homology <IMM>
 F;41-115/Disulfide bonds: #status predicted
```

```
Query Match
                       70.9%; Score 510; DB 1; Length 117;
 Best Local Similarity
                       83.8%; Pred. No. 1.5e-37;
          98; Conservative
                             6; Mismatches
                                           13; Indels
                                                              Gaps
                                                                     0;
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            Db
          1 MNFGLRLIFLVLTLKGVKCEVOLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVROTP 60
         61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR 117
Qγ
            61 EKRLEWVAYISSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCAR 117
Db
RESULT 12
S31615
hypothetical protein - mouse (fragment)
C; Species: Mus musculus (house mouse)
C; Date: 13-Jan-1995 #sequence revision 13-Jan-1995 #text change 23-Jul-1999
C; Accession: S31615
R; Recinos, A.; Silvey, K.J.; Jensen, R.H.; Stanker, L.H.
submitted to the EMBL Data Library, April 1991
A; Description: Immunoglobulin variable heavy and light chain cDNA sequences for
antidioxin monoclonal.
A; Reference number: S31615
A; Accession: S31615
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-136 < REC>
A; Cross-references: EMBL: X58884; NID: g51824; PIDN: CAA41688.1; PID: g51825
C; Superfamily: immunoglobulin V region; immunoglobulin homology
F; 34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                       70.7%; Score 508; DB 2; Length 136;
                       70.3%; Pred. No. 2.6e-37;
 Best Local Similarity
          97; Conservative 16; Mismatches
                                             23;
                                                 Indels
                                                              Gaps
                                                                     1;
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
            1 MNFGLRLIFLVLTLKGVQCDVNLVESGGGLVKPGGTLKLSCSASGFAFSTYSMVWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
            Db
          61 EKRLEWVATITGGGTYTYYPDSVRGRFTISRDNARDTLNLHMTNLKSEDTAMYYCLGYYW 120
         121 YSGSSDYWGQGTTVTVSS 138
Qу
            1 1: 11111 1 11:
         121 YDGT--YWGQGTLVIVSA 136
Db
RESULT 13
S22657
Ig heavy chain precursor V region (0-81VH) - human (fragment)
C; Species: Homo sapiens (man)
C; Date: 29-Jan-1998 #sequence revision 06-Feb-1998 #text change 06-Feb-1998
C; Accession: S22657
R; Hirabayashi, Y.; Munakata, Y.; Sasaki, T.; Sano, H.
Nucleic Acids Res. 20, 2601, 1992
```

```
A; Title: Variable regions of a human anti-DNA antibody O-81 possessing lupus
nephritis-associated idiotype.
A; Reference number: S22657; MUID: 92285150; PMID: 1598223
A; Accession: S22657
A; Molecule type: mRNA
A; Residues: 1-140 <HIR>
A; Cross-references: EMBL: X59134
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                         70.1%; Score 504; DB 2; Length 140;
 Best Local Similarity
                         68.1%; Pred. No. 6e-37;
           94; Conservative
                               21; Mismatches
                                                19;
                                                     Indels
                                                               4; Gaps
                                                                           1;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             Db
           1 MEFGLSWVFLVAILEGVQCEVQLVESGGGLVQPGGSLRLSCAASGFTFSSHWMTWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              |||||||||
                             61 GKRLEWVANVKQDGSARYYADSVRGRFTISRDNAKNSLYLQMDSLRADDTAVYYCAR--- 117
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
                  1
         118 -STGIDYWGQGTLVTVSS 134
Dh
RESULT 14
G1MS21
Ig heavy chain precursor V region (MOPC 21) - mouse (fragment)
C; Species: Mus musculus (house mouse)
C; Date: 02-Apr-1982 #sequence revision 02-Apr-1982 #text change 09-Jul-2004
C; Accession: E90809; A93184; A02066
R; Bothwell, A.L.M.; Paskind, M.; Reth, M.; Imanishi-Kari, T.; Rajewsky, K.;
Baltimore, D.
Cell 24, 625-637, 1981
A; Title: Heavy chain variable region contribution to the NP(b) family of
antibodies: somatic mutation evident in a gamma2a variable region.
A; Reference number: A90809; MUID: 81234548; PMID: 6788376
A; Accession: E90809
A; Molecule type: mRNA
A; Residues: 1-136 <BOT>
A; Cross-references: UNIPROT: P01783; GB: J00522; NID: g195052; PIDN: AAD15290.1;
PID:q195055
R; Adetugbo, K.; Milstein, C.; Secher, D.S.
Nature 265, 299-304, 1977
A; Title: Molecular analysis of spontaneous somatic mutants.
A; Reference number: A93184; MUID: 77100368; PMID: 401950
A; Contents: myeloma protein MOPC 21
A; Accession: A93184
A; Molecule type: protein
A; Residues: 17-74, 'D', 76-77, 'H', 79-88, 'ND', 91-114, 'H', 116-119, 'W', 121-136 <ADE>
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
```

```
F;1-16/Domain: signal sequence (fragment) #status predicted <SIG>
F;17-136/Product: Ig heavy chain V region (MOPC 21) #status.experimental <MAT>
F;31-114/Domain: immunoglobulin homology <IMM>
F;115-119/Region: D segment
F;120-136/Region: J segment (JH4)
F;38-112/Disulfide bonds: #status experimental
 Query Match
                        69.9%; Score 502.5; DB 1;
                                                   Length 136;
 Best Local Similarity
                        70.4%; Pred. No. 7.8e-37;
 Matches
           95; Conservative
                             20: Mismatches
                                              19:
                                                   Indels
                                                            1; Gaps
                                                                       1;
           5 LSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNSDKRL 64
Qу
             2 LNLVFLVLILKGVQCDVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGL 61
          65 EWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDHYS-G 123
Qу
                         62 EWVAYISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARWGNYPYY 121
Db
         124 SSDYWGQGTTVTVSS 138
Qу
             : | | | | | | | | | | | | | | | | | |
Db
         122 AMDYWGQGTSVTVSS 136
RESULT 15
S31666
Ig heavy chain V region - human (fragment)
C; Species: Homo sapiens (man)
C; Date: 22-Nov-1993 #sequence revision 10-Nov-1995 #text change 23-Jul-1999
C; Accession: S31666
R; Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A; Description: Mechanisms that generate human immunoglobulin diversity operate
from the 8th week of gestation in feral liver.
A; Reference number: S31585
A; Accession: S31666
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-138 <CUI>
A; Cross-references: EMBL: Z14202; NID: g30963; PIDN: CAA78571.1; PID: g30964
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>
 Query Match
                        69.8%; Score 502; DB 2; Length 138;
 Best Local Similarity 67.6%; Pred. No. 8.8e-37;
 Matches
           96; Conservative 21; Mismatches
                                             17: Indels
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRONS 60
Qy
             Db
           1 MEFGLSWLFLVAILKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
Qу
                         61 GKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKART 120
Db
         118 -YDHYSGSSDYWGQGTTVTVSS 138
Qу
```

| :: | ||:|| |||| 121 GYWYF----DLWGRGTLVTVSS 13.8

Search completed: December 13, 2004, 19:18:39
Job time: 24.5333 secs

## GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 13, 2004, 19:17:53; Search time 99.1556 Seconds

(without alignments)

497.104 Million cell updates/sec

Title: US-10-010-942B-4

Perfect score: 719

Sequence: 1 MNFGLSLIFLVLVLKGVQCE.....DHYSGSSDYWGQGTTVTVSS 138

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 1585576 segs, 357178320 residues

Total number of hits satisfying chosen parameters: 1585576

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Published Applications AA:\*

- 1: /cgn2 6/ptodata/2/pubpaa/US07 PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW PUB.pep:\*
- 3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep:\*
- 4: /cgn2 6/ptodata/2/pubpaa/US06 PUBCOMB.pep:\*
- 5: /cgn2 6/ptodata/2/pubpaa/US07 NEW PUB.pep:\*
- 6: /cgn2 6/ptodata/2/pubpaa/PCTUS PUBCOMB.pep:\*
- 7: /cgn2 6/ptodata/2/pubpaa/US08 NEW PUB.pep:\*
- 8: /cgn2 6/ptodata/2/pubpaa/US08 PUBCOMB.pep:\*
- 9: /cgn2 6/ptodata/2/pubpaa/US09A PUBCOMB.pep:\*
- 10: /cgn2 6/ptodata/2/pubpaa/US09B PUBCOMB.pep:\*
- 11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep:\*
- 12: /cgn2\_6/ptodata/2/pubpaa/US09 NEW PUB.pep:\*
- 13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep:\*
- 14: /cgn2 6/ptodata/2/pubpaa/US10B PUBCOMB.pep:\*
- 15: /cgn2 6/ptodata/2/pubpaa/US10C PUBCOMB.pep:\*
- 16: /cgn2 6/ptodata/2/pubpaa/US10D PUBCOMB.pep:\*
- 17: /cgn2 6/ptodata/2/pubpaa/US10 NEW PUB.pep:\*
- 18: /cgn2\_6/ptodata/2/pubpaa/US11\_NEW\_PUB.pep:\*
- 19: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep:\*
- 20: /cgn2 6/ptodata/2/pubpaa/US60 PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Re:	sult		Query	i.			•
	No.	Score	Match	Length	DB	ID	Description
	1	. 719	100.0	138	14	US-10-010-942B-4	Sequence 4, Appli
	2	719	100.0	138	15	US-10-388-389-4	Sequence 4, Appli
	3	719	100.0	138	16	US-10-703-713-4	Sequence 4, Appli
	4	719	100.0	138	16	US-10-704-070-4	Sequence 4, Appli
	5	652	90.7	138	14	US-10-010-942B-8	Sequence 8, Appli
	6	652	90.7	138	15	US-10-388-389-8	Sequence 8, Appli
	7	652	90.7	138	16	US-10-703-713-8	Sequence 8, Appli
	8	652	90.7	138	16	US-10-704-070-8	Sequence 8, Appli
	9	650	90.4	138	14	US-10-010-942B-12	Sequence 12, Appl
	10	650	90.4	138	15	US-10-388-389-12	Sequence 12, Appl
	11	650	90.4	138	16	US-10-703-713-12	Sequence 12, Appl
	12	650	90.4	138	16	US-10-704-070-12	Sequence 12, Appl
	13	609.5	84.8	133	13	US-10-006-773-9	Sequence 9, Appli
	14	578.5	80.5	139	13	US-10-006-773-17	Sequence 17, Appl
	15	578	80.4	462	14	US-10-281-479A-23	Sequence 23, Appl
	16	578	80.4	462	14	US-10-286-132A-23	Sequence 23, Appl
	17	578	80.4	464	14	US-10-275-180A-23	Sequence 23, Appl
	18	569	79.1	144	9	US-09-881-823-12	Sequence 12, Appl
	19	566	78.7	140	9	US-09-286-240-4	Sequence 4, Appli
	20	559	77.7	140	13	US-10-006-773-4	Sequence 4, Appli
	21	557.5	77.5	137	19	US-09-423-8 <u>0</u> 00-76	Sequence 76, Appl
	22	557.5	77.5	137	14	US-10-337-981-76	Sequence 76, Appl
	23	553	76.9	158	15	US-10-226-795-32	Sequence 32, Appl
	24	549	76.4	140	14	US-10-283-349-23	Sequence 23, Appl
	25	542	75.4	140	15	US-10-365-123-51	Sequence 51, Appl
	26	537	74.7	159	14	US-10-291-265-333	Sequence 333, App
	27	531.5	73.9	143	10	US-09-791-551-117	Sequence 117, App
	28	528	73.4	143	15	US-10-469-304-17	Sequence 17, Appl
	29	526.5	73.2	177	16	US-10-693-629-64	Sequence 64, Appl
	30	522	72.6	313	14	US-10-291-265-427	Sequence 427, App
	31	522	72.6	470	15	US-10-038-591-46	Sequence 46, Appl
	32	522	72.6	470	17	US-10-775-444A-46	Sequence 46, Appl
	33	520.5	72.4	469	14	US-10-292-088-54	Sequence 54, Appl
	34	514.5	71.6	139	10	US-09-947-839-96	Sequence 96, Appl
	35	514.5	71.6	139	17	US-10-478-056-33	Sequence 33, Appl
	36	514	71.5	138	9	US-09-796-744-15	Sequence 15, Appl
	37	514	71.5	138	14	US-10-231-452-62	Sequence 62, Appl
	38	512	71.2	465	14	US-10-401-344-2	Sequence 2, Appli
	39	510.5	71.0	137	9	US-09-423-800-77	Sequence 77, Appl
	40	510.5	71.0	137	14	US-10-337-981-77	Sequence 77, Appl
	41	510.5	71.0	473	15	US-10-038-591-50	Sequence 50, Appl
	42	510.5	71.0	473	17	US-10-775-444A-50	Sequence 50, Appl
	43	508.5	70.7	307	14	US-10-291-265-332	Sequence 332, App
	44	508.5	70.7	363	14	US-10-291-265-335	Sequence 335, App
	45	506	70.4	474	10	US-09-848-832-3	Sequence 3, Appli
							· ·

## ALIGNMENTS

## RESULT 1

US-10-010-942B-4

<sup>;</sup> Sequence 4, Application US/10010942B ; Publication No. US20030165496A1

```
; GENERAL INFORMATION:
  APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002
  CURRENT APPLICATION NUMBER: US/10/010,942B
  CURRENT FILING DATE: 2002-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Mus musculus
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-010-942B-4
                        100.0%; Score 719; DB 14; Length 138;
 Query Match
 Best Local Similarity
                        100.0%; Pred. No. 6.6e-60;
                              0; Mismatches
                                                   Indels
                                                                        0:
                                               0;
 Matches 138; Conservative
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qy
             61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
             1111111111111111
        121 YSGSSDYWGQGTTVTVSS 138
Db
RESULT 2
US-10-388-389-4
; Sequence 4, Application US/10388389
; Publication No. US20040087777A1
; GENERAL INFORMATION:
  APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
   FILE REFERENCE: ELN-002CP
   CURRENT APPLICATION NUMBER: US/10/388,389
   CURRENT FILING DATE: 2003-03-12
   PRIOR APPLICATION NUMBER: US 10/010,942
   PRIOR FILING DATE: 2001-12-06
   PRIOR APPLICATION NUMBER: US 60/251,892
   PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
```

```
SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Mus musculus
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-388-389-4
                        100.0%; Score 719; DB 15; Length 138;
 Query Match
                        100.0%; Pred. No. 6.6e-60;
 Best Local Similarity
                                                                         0;
                                                    Indels
                                                                 Gaps
 Matches 138; Conservative 0; Mismatches
                                               0;
           1 \hspace{0.1cm} \texttt{MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS} \hspace{0.1cm} \textbf{60} \\
Qу
             1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qy
             61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
QУ
             11111111111111111
         121 YSGSSDYWGQGTTVTVSS 138
Db
RESULT 3
US-10-703-713-4
; Sequence 4, Application US/10703713
; Publication No. US20040171815A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/703,713
  CURRENT FILING DATE: 2003-11-07
  PRIOR APPLICATION NUMBER: US/10/388,389
  PRIOR FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Mus musculus
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-703-713-4
```

```
100.0%; Score 719; DB 16;
                                                Length 138;
 Query Match
                      100.0%; Pred. No. 6.6e-60;
 Best Local Similarity
 Matches 138; Conservative
                             0: Mismatches
                                                Indels
                                                             Gaps
                                                                    0;
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
            1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Db
         61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
            61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Db
        121 YSGSSDYWGQGTTVTVSS 138
Qу
            111111111111111111
        121 YSGSSDYWGQGTTVTVSS 138
Db
RESULT 4
US-10-704-070-4
; Sequence 4, Application US/10704070
; Publication No. US20040171816A1
; GENERAL INFORMATION:
  APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/704,070
  CURRENT FILING DATE: 2003-11-07
  PRIOR APPLICATION NUMBER: 10/388,389
  PRIOR FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
 SEO ID NO 4
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Mus musculus
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-704-070-4
                       100.0%; Score 719; DB 16;
  Query Match
                       100.0%; Pred. No. 6.6e-60;
  Best Local Similarity
                                                                    0;
                             0; Mismatches
                                             0;
                                                Indels
                                                         0:
                                                             Gaps
  Matches 138; Conservative
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qy
```

```
61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
QУ
             1111111111111111
         121. YSGSSDYWGQGTTVTVSS 138
Db
RESULT 5
US-10-010-942B-8
; Sequence 8, Application US/10010942B
; Publication No. US20030165496A1
; GENERAL INFORMATION:
 APPLICANT: Basi, Guriq
 APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002
  CURRENT APPLICATION NUMBER: US/10/010,942B
  CURRENT FILING DATE: 2002-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Humanized 3D6 heavy chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-010-942B-8
                        90.7%; Score 652; DB 14; Length 138;
  Query Match
  Best Local Similarity
                        89.1%; Pred. No. 1.3e-53;
                              9; Mismatches
                                                  Indels
 Matches 123; Conservative
                                               6;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qy
              61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qy
             11111111111 1111
         121 YSGSSDYWGQGTLVTVSS 138
Db
RESULT 6
US-10-388-389-8
; Sequence 8, Application US/10388389
; Publication No. US20040087777A1
```

; GENERAL INFORMATION:

```
APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/388,389
  CURRENT FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Humanized 3D6 heavy chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-388-389-8
                        90.7%; Score 652; DB 15; Length 138;
 Query Match
                        89.1%; Pred. No. 1.3e-53;
 Best Local Similarity
                                                                       0;
 Matches 123; Conservative 9; Mismatches 6;
                                                            0; Gaps
                                                   Indels
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qy
             111111111111 1111
         121 YSGSSDYWGQGTLVTVSS 138
Db
RESULT 7
US-10-703-713-8
; Sequence 8, Application US/10703713
; Publication No. US20040171815A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/703,713
  CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: US/10/388,389
  PRIOR FILING DATE: 2003-03-12
```

```
PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO 8
  LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Humanized 3D6 heavy chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-703-713-8
                        90.7%; Score 652; DB 16; Length 138;
 Query Match
 Best Local Similarity 89.1%; Pred. No. 1.3e-53;
 Matches 123; Conservative
                                              6; Indels 0; Gaps
                             9; Mismatches
                                                                       0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
Qу
             11111111111
         121 YSGSSDYWGQGTLVTVSS 138
Db
RESULT 8
US-10-704-070-8
; Sequence 8, Application US/10704070
; Publication No. US20040171816A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted.
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/704,070
  CURRENT FILING DATE: 2003-11-07
  PRIOR APPLICATION NUMBER: 10/388,389
  PRIOR FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
   LENGTH: 138
```

```
ORGANISM: Artificial Sequence
   OTHER INFORMATION: Humanized 3D6 heavy chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-704-070-8
 Query Match
                        90.7%; Score 652; DB 16; Length 138;
 Best Local Similarity
                        89.1%; Pred. No. 1.3e-53;
 Matches 123; Conservative
                              9; Mismatches
                                                  Indels
                                                                       0;
                                               6;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qy
              61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNAKNSLYLOMNSLRAEDTALYYCVRYDH 120
Db
         121 YSGSSDYWGQGTTVTVSS 138
QУ
             11111111111
Db
         121 YSGSSDYWGQGTLVTVSS 138
RESULT 9
US-10-010-942B-12
; Sequence 12, Application US/10010942B
; Publication No. US20030165496A1
; GENERAL INFORMATION:
 APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002
  CURRENT APPLICATION NUMBER: US/10/010,942B
  CURRENT FILING DATE: 2002-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEO ID NO 12
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   OTHER INFORMATION: Humanized 3D6 light chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-010-942B-12
                        90.4%; Score 650; DB 14; Length 138;
 Query Match
                        88.4%; Pred. No. 2.1e-53;
 Best Local Similarity
 Matches 122; Conservative 10; Mismatches
                                                   Indels
                                                            0;
                                                                       0;
                                                                Gaps
```

TYPE: PRT

```
1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
            1 \ \mathtt{MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP} \ \ 60
Db
         61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
QУ
             61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDH 120
Db
        121 YSGSSDYWGQGTTVTVSS 138
Qу
            121 YSGSSDYWGQGTLVTVSS 138
Db
RESULT 10
US-10-388-389-12
; Sequence 12, Application US/10388389
; Publication No. US20040087777A1
; GENERAL INFORMATION:
  APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/388,389
  CURRENT FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Humanized 3D6 light chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-388-389-12
                      90.4%; Score 650; DB 15; Length 138;
 Query Match
 Best Local Similarity 88.4%; Pred. No. 2.1e-53;
 Matches 122; Conservative 10; Mismatches
                                                                   0;
                                           6; Indels
                                                         0; Gaps
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
         61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDH 120
Db
        121 YSGSSDYWGQGTTVTVSS 138
Qy
```

Db

```
RESULT 11
US-10-703-713-12
; Sequence 12, Application US/10703713
; Publication No. US20040171815A1
; GENERAL INFORMATION:
  APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/703,713
  CURRENT FILING DATE: 2003-11-07
  PRIOR APPLICATION NUMBER: US/10/388,389
  PRIOR FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Humanized 3D6 light chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-703-713-12
 Query Match
                        90.4%; Score 650; DB 16; Length 138;
 Best Local Similarity 88.4%; Pred. No. 2.1e-53;
 Matches 122; Conservative 10; Mismatches
                                             6; Indels
                                                            0;
                                                               Gaps
                                                                       0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             Db
           1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              Db
          61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDH 120
       121 YSGSSDYWGQGTTVTVSS 138
Qу
             11111111111 1111
Db
         121 YSGSSDYWGQGTLVTVSS 138
```

### RESULT 12

US-10-704-070-12

- ; Sequence 12, Application US/10704070
- ; Publication No. US20040171816A1

```
; GENERAL INFORMATION:
  APPLICANT: Basi, Guriq
  APPLICANT: Saldanha, Jose
  APPLICANT: Yednock, Ted
  TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
  TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
  FILE REFERENCE: ELN-002CP
  CURRENT APPLICATION NUMBER: US/10/704,070
  CURRENT FILING DATE: 2003-11-07
  PRIOR APPLICATION NUMBER: 10/388,389
  PRIOR FILING DATE: 2003-03-12
  PRIOR APPLICATION NUMBER: US 10/010,942
  PRIOR FILING DATE: 2001-12-06
  PRIOR APPLICATION NUMBER: US 60/251,892
  PRIOR FILING DATE: 2000-12-06
  NUMBER OF SEQ ID NOS: 63
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEO ID NO 12
   LENGTH: 138
   TYPE: PRT
   ORGANISM: Artificial Sequence
   OTHER INFORMATION: Humanized 3D6 light chain variable region
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: (1)...(19)
US-10-704-070-12
                        90.4%; Score 650; DB 16; Length 138;
 Query Match
                        88.4%; Pred. No. 2.1e-53;
 Best Local Similarity
 Matches 122; Conservative 10; Mismatches
                                              6;
                                                   Indels
                                                            0;
                                                                Gaps
                                                                        0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
              Db
          61 GKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDH 120
         121 YSGSSDYWGQGTTVTVSS 138
Qv
             111111111
         121 YSGSSDYWGQGTLVTVSS 138
Db
RESULT 13
US-10-006-773-9
; Sequence 9, Application US/10006773
; Publication No. US20020132983A1
; GENERAL INFORMATION:
; APPLICANT: Junghans, Richard P.
  TITLE OF INVENTION: Antibodies as Chimeric Effector Cell Receptors Against
Tumor Antigens
; FILE REFERENCE: 003
  CURRENT APPLICATION NUMBER: US/10/006,773
  CURRENT FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/250,089
```

```
PRIOR FILING DATE: 2000-11-30
  NUMBER OF SEQ ID NOS: 19
  SOFTWARE: PatentIn version 3.1
 SEQ ID NO 9
   LENGTH: 133
   TYPE: PRT
   ORGANISM: Mus sp.
US-10-006-773-9
 Query Match
                      84.8%; Score 609.5; DB 13;
                                                 Length 133;
                      87.0%; Pred. No. 1.3e-49;
 Best Local Similarity
 Matches 120; Conservative
                             6; Mismatches
                                            7;
                                                Indels
                                                                   1;
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
            1 MNFGLSLIFLVLVLKGVQCEVKVVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTS 60
Db
         61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
            61 DKRLEWVASISSGGDSTFYADNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCARDDL 120
Db
        121 YSGSSDYWGOGTTVTVSS 138
Qу
                  111111:111
        121 FN-----WGQGTTLTVSS 133
Db
RESULT 14
US-10-006-773-17
; Sequence 17, Application US/10006773
; Publication No. US20020132983A1
; GENERAL INFORMATION:
  APPLICANT: Junghans, Richard P.
  TITLE OF INVENTION: Antibodies as Chimeric Effector Cell Receptors Against
Tumor Antigens
  FILE REFERENCE: 003
  CURRENT APPLICATION NUMBER: US/10/006,773
  CURRENT FILING DATE: 2001-12-10
  PRIOR APPLICATION NUMBER: 60/250,089
  PRIOR FILING DATE: 2000-11-30
  NUMBER OF SEQ ID NOS: 19
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
   LENGTH: 139
   TYPE: PRT
   ORGANISM: Mus sp.
US-10-006-773-17
                       80.5%; Score 578.5; DB 13;
                                                 Length 139;
 Query Match
 Best Local Similarity
                             Pred. No. 1.1e-46;
                       82.7%;
                               Mismatches
                                            17;
                                                            Gaps
                                                                    1;
 Matches 115; Conservative
                             6;
                                                Indels
                                                         1:
          1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
            1 MNFGLSLIFLVLVLKGVQCEVKLVESGGDLMNPGASLKLSCAASGFSFSNYGMSWVRQTS 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
```

```
121 YSGS-SDYWGOGTTVTVSS 138
Qу
               1
                    | | | | | | | | | | | | | | | | | |
         121 SVGCWFATWGQGTLVTVSA 139
Db
RESULT 15
US-10-281-479A-23
; Sequence 23, Application US/10281479A
; Publication No. US20030133932A1
; GENERAL INFORMATION:
  APPLICANT: The UAB Research Foundation
  APPLICANT: Zhou, Tong
  APPLICANT: Ichikawa, Kimihisa
  APPLICANT: Kimberly, Robert P.
  APPLICANT: Koopman, William J.
  APPLICANT: Oshumi, Jun
  APPLICANT: LoBuglio, Albert S.
 APPLICANT: Buchsbaum, Donald J.
  TITLE OF INVENTION: COMBINATIONS OF ANTIBODIES SELECTIVE FOR A TUMOR NECROSIS
  TITLE OF INVENTION: FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND
OTHER THERAPEUTIC
  TITLE OF INVENTION: AGENTS
  FILE REFERENCE: 21085.0029U6
  CURRENT APPLICATION NUMBER: US/10/281,479A
  CURRENT FILING DATE: 2003-01-28
  PRIOR APPLICATION NUMBER: 60/391,478
  PRIOR FILING DATE: 2002-06-24
  PRIOR APPLICATION NUMBER: 60/346,402
  PRIOR FILING DATE: 2001-11-01
  PRIOR APPLICATION NUMBER: PCT/US01/14151
  PRIOR FILING DATE: 2001-05-02
  PRIOR APPLICATION NUMBER: 60/201,344
  PRIOR FILING DATE: 2000-05-02
  NUMBER OF SEQ ID NOS: 102
  SOFTWARE: PatentIn version 3.0
 SEQ ID NO 23
   LENGTH: 462
   TYPE: PRT
   ORGANISM: artificial sequence
   OTHER INFORMATION: Description of Artificial Sequence:/No. US20030133932Ale
= Synthetic Construct
US-10-281-479A-23
                        80.4%; Score 578; DB 14;
                                                   Length 462;
  Query Match
                        81.2%; Pred. No. 4.8e-46;
  Best Local Similarity
                                                                         0;
  Matches 112; Conservative 10; Mismatches
                                               16;
                                                   Indels
                                                             0;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYVMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
Qу
             61 EKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRGD 120
Db
```

61 DKRLEWVASISTGGANTFYPDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYFCARDSH 120

Db

Qy 121 YSGSSDYWGQGTTVTVSS 138

::|||||||

Db 121 SMITTDYWGQGTTLTVSS 138

Search completed: December 13, 2004, 19:34:50

Job time : 100.156 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 13, 2004, 18:50:06; Search time 131.356 Seconds

(without alignments)

604.479 Million cell updates/sec

er en en vage a data

Title: US-10-010-942B-4

Perfect score: 719

Sequence: 1 MNFGLSLIFLVLVLKGVQCE.....DHYSGSSDYWGQGTTVTVSS 138

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: UniProt 02:\*

1: uniprot\_sprot:\*
2: uniprot\_trembl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

			8				
R	esult		Query			,	
_	No.	Score	Match	Length	DB	ID	Description
	1	576.5	80.2	487	2	Q99KA4	Q99ka4 mus musculu
	. 2	557	77.5	479	2	Q91WP5	Q91wp5 mus musculu
	3	547	76.1	486	2	Q91Z07	Q91z07 mus musculu
	4	529	73.6	485	2	Q6PDB8	Q6pdb8 mus musculu
	5	529	73.6	485	2	AAH58814	Aah58814 mus muscu
	6	516.5	71.8	473	2	Q91Z05	Q91z05 mus musculu
	7	512	71.2	117	1	HV54 MOUSE	P18525 mus musculu
	8	510	70.9	117	1	HV55 MOUSE	P18526 mus musculu
	9	505	70.2	480	2	Q91XE1	` Q91xe1 mus musculu
	10	503	70.0	597	2	Q96BB9	Q96bb9 homo sapien
	11	502.5	69.9	136	1	HV16 MOUSE	P01783 mus musculu
	12	501	69.7	117	1	HV59 MOUSE	P18530 mus musculu
	13	499	69.4	478	2	Q6PI81	Q6pi81 homo sapien
~	14	499	69.4	478	2	AAH41037	Aah41037 homo sapi
	15	495.5	68.9	606	2	Q6GMY2	Q6gmy2 homo sapien

16	492	68.4	117	1	HV53_MOUSE	P18524 mus musculu
17	492	68.4	119	2	Q920E7	Q920e7 mus musculu
18	490	68.2	255	2	Q6KB05	Q6kb05 mus musculu
19	490	68.2	255	2	CAG34081	Cag34081 mus muscu
20	490	68.2	499	2	Q8N5K4	Q8n5k4 homo sapien
21	487	67.7	464	2	Q6MZU6	Q6mzu6 homo sapien
22	487	67.7	464	2	CAE45931	Cae45931 homo sapi
23	486.5	67.7	613	2	Q8WUK1	Q8wuk1 homo sapien
24	486	67.6	470	2	Q6PJA4	Q6pja4 homo sapien
25	486	67.6	470	2	AAH18747	Aah18747 homo sapi
26	484	67.3	117	1	HV58 MOUSE	P18529 mus musculu
27	483.5	67.2	573	2	Q8WU38	Q8wu38 homo sapien
28	477.5	66.4	471	2	AAH24289	Aah24289 homo sapi
29	475	66.1	472	2	Q6N089	Q6n089 homo sapien
30	475	66.1	472	2	CAE45781	Cae45781 homo sapi
31	473	65.8	493	2	Q6GMX2	Q6gmx2 homo sapien
32	471	65.5	493	2	Q8NCL6	Q8ncl6 homo sapien
33	468.5	65.2	475	2	Q6MZQ6	Q6mzq6 homo sapien
34	468.5	65.2	475	2	CAE45972	Cae45972 homo sapi
35	464	64.5	128	2	BAD00406	Bad00406 camelus d
36	464	64.5	464	2	BAC85395	Bac85395 homo sapi
37	463.5	64.5	465	2	Q6P6C4	Q6p6c4 homo sapien
38	463.5	64.5	465	2	AAH62335	Aah62335 homo sapi
39	463	64.4	117	1	HV3C_HUMAN	P01764 homo sapien
40	463	64.4	117	2	AAL35877	Aal35877 lama glam
41	462.5	64.3	479	2	AAH06402	Aah06402 homo sapi
42	461.5	64.2	494	2	Q96K68	Q96k68 homo sapien
43	460.5	64.0	473	2	Q6MZV7	Q6mzv7 homo sapien
44	460.5	64.0	473	2	CAE45920	Cae45920 homo sapi
45	460	64.0	497	2	BAC86210	Bac86210 homo sapi

## ALIGNMENTS

```
RESULT 1
Q99KA4
                 PRELIMINARY;
ID
     Q99KA4
                                    PRT;
                                           487 AA.
AC
     099KA4;
DT
     01-JUN-2001 (TrEMBLrel. 17, Created)
     01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
     01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DT
DE
     LOC380791 protein.
OS
     Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
     NCBI TaxID=10090;
OX
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=Czech II;
RC
     TISSUE=Mammary tumor metastatized to lung. Tumor arose spontaneously;
RX
     MEDLINE=22388257; PubMed=12477932;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
```

```
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
RA
     Jones S.J., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length human
     and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [2]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=Czech II;
RC
     TISSUE=Mammary tumor metastatized to lung. Tumor arose spontaneously;
RA.
     Strausberg R.;
RL
     Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
     EMBL; BC004786; AAH04786.1; -.
DR
    HSSP; P01810; 2FBJ.
DR
DR
     InterPro; IPR007110; Ig-like.
     InterPro; IPR003597; Ig_c1.
DR
DR
     InterPro; IPR003006; Iq MHC.
     InterPro; IPR003596; Ig v.
DR
DR
     Pfam; PF07654; C1-set; 2.
     Pfam; PF00047; iq; 1.
DR
DR
     SMART; SM00406; IGv; 1.
     PROSITE; PS50835; IG LIKE; 4.
DR
     PROSITE; PS00290; IG MHC; UNKNOWN 2.
DR
SQ
               487 AA; 52554 MW; 7DC8E96DB333077B CRC64;
  Query Match
                         80.2%;
                                Score 576.5; DB 2;
                                                    Length 487;
  Best Local Similarity
                         79.2%; Pred. No. 4.6e-49;
 Matches 114; Conservative
                               7; Mismatches
                                                16;
                                                     Indels
                                                              7;
                                                                  Gaps
                                                                          2;
Qу
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
             Db
           1 MNFGLSLIFLVLVLKGVQCEVQLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
Qу
             Db
          61 EKRLEWVATISDGGSYTYYPDNVKGRFTISRDNAKNNLYLOMSHLKSEDTAMYYCARDMG 120
Qу
         118 ---YDHYSGSSDYWGQGTTVTVSS 138
                1 11
                       Db
         121 GSPYGGYS-RFDYWGQGTTITVSS 143
RESULT 2
Q91WP5
ID
    Q91WP5
                PRELIMINARY;
                                 PRT;
                                        479 AA.
AC
    Q91WP5;
DT
     01-DEC-2001 (TrEMBLrel. 19, Created)
DT
     01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
```

```
DE
     Igh-VJ558 protein.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RC
     STRAIN=FVB/N; TISSUE=Colon;
RX
    MEDLINE=22388257; PubMed=12477932;
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
RA___
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
    Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
RA
    Jones S.J., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length human
    and mouse cDNA sequences.";
RT
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [2]
    SEQUENCE FROM N.A.
RP
     STRAIN=FVB/N; TISSUE=Colon;
RC
    Strausberg R.;
RA
RL
    Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC013656; AAH13656.1; -.
DR
    HSSP; P01789; 1MCP.
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig cl.
DR
     InterPro; IPR003006; Ig MHC.
DR
DR
     InterPro; IPR003596; Ig v.
     Pfam; PF07654; C1-set; 2.
DR
DR
     Pfam; PF00047; ig; 1.
DR
     SMART; SM00406; IGv; 1.
DR
     PROSITE; PS50835; IG LIKE; 4.
     PROSITE; PS00290; IG MHC; UNKNOWN 2.
DR
SQ
     SEQUENCE
               479 AA; 51603 MW; ECB2D0877748584F CRC64;
                         77.5%;
                                 Score 557; DB 2; Length 479;
  Query Match
  Best Local Similarity
                         78.3%; Pred. No. 4e-47;
  Matches 108; Conservative 10; Mismatches
                                                16; Indels
                                                                            1;
Qу
            1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
              1 MNFGLTLIFLVLTLKGVQCEVQLVESGGGLVKPGGSLKVSCAASGLTFSNYAMSWVRQSP 60
Db
Qу
           61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
```

01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DT

```
61 EKRLEWVAAINSNGGNTYYSDTMKGRFTISRDNAKSTLYLQMSSLRSEDTAFYYCVR--- 117
Db
          121 YSGSSDYWGQGTTVTVSS 138
Qу
                118 -GGYFDVWGAGTAVTVSS 134
Db
RESULT 3
Q91Z07
ID
    Q91Z07
                 PRELIMINARY;
                                   PRT;
                                          486 AA.
AC
     Q91Z07;
DT
     01-DEC-2001 (TrEMBLrel. 19, Created)
     01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
     01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DT
DE
     LOC380791 protein.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
     [1]
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=Czech II;
    TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC
RC
     Expression driven by an MMTV-LTR enhancer.;
RX
    MEDLINE=22388257; PubMed=12477932;
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
RA
     Jones S.J., Marra M.A.;
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RT
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
                                                                                early - Const
RN
     [2]
ŘΡ
     SEQUENCE FROM N.A.
RC
     STRAIN=Czech II;
     TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC
RC
     Expression driven by an MMTV-LTR enhancer.;
RA ·
     Strausberg R.;
     Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RL
DR
     EMBL; BC010324; AAH10324.1; -.
     HSSP; P01789; 1MCP.
DR
     InterPro; IPR007110; Ig-like.
DR
     InterPro; IPR003597; Ig c1.
DR
```

```
InterPro; IPR003006; Ig MHC.
DR
DR
    InterPro; IPR003596; Ig v.
    Pfam; PF07654; C1-set; 2.
DR
    Pfam; PF00047; ig; 1.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
DR
    PROSITE; PS00290; IG MHC; UNKNOWN 2.
               486 AA; 52681 MW; 4FEF835125DA870B CRC64;
    SEOUENCE
SQ
 Query Match
                         76.1%; Score 547; DB 2;
                                                   Length 486;
 Best Local Similarity
                         76.2%; Pred. No. 4.1e-46;
                                                16; Indels
 Matches 109; Conservative 12; Mismatches
                                                               6;
                                                                  Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLRLIFLVLALKGVQCEVHLVESGGGLVKPGGSLKLSCVVSGFSFTSYDMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYD- 119
Qу
             61 ERRLEWVAAITS-GGNTYYPDNVKGRFTVSRDNAKYTLYLQMSSLKSEDTAMYYCVRPEI 119
Db
         120 --- HYSGS-SDYWGQGTTVTVSS 138
Qу
                120 PIYYYSGSYFDSWGQGTTITVSS 142
Db
RESULT 4
Q6PDB8
                PRELIMINARY;
                                  PRT;
                                        485 AA.
ID
    Q6PDB8
    Q6PDB8;
AC
     05-JUL-2004 (TrEMBLrel. 27, Created)
DT
     05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT
     05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DT
DE
     Hypothetical protein.
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
     [1]
     SEQUENCE FROM N.A.
RP
     STRAIN=FVB/N; TISSUE=Colon;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
```

```
RA
       Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
       Jones S.J., Marra M.A.;
  RA
       "Generation and initial analysis of more than 15,000 full-length human
  RT
  RT
       and mouse cDNA sequences.";
       Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
  RL
  RN
  RP
       SEQUENCE FROM N.A.
       STRAIN=FVB/N; TISSUE=Colon;
  RC
       Strausberg R.;
  RA
       Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
  RL
       EMBL; BC058814; AAH58814.1; -.
  DR
  DR
       InterPro; IPR003599; Ig.
       InterPro; IPR007110; Ig-like.
  DR
       InterPro; IPR003597; Ig c1.
  DR
       InterPro; IPR003006; Ig MHC.
  DR
       InterPro; IPR003596; Ig v.....
  DR
       Pfam; PF07654; C1-set; 2.
  DR
       Pfam; PF00047; ig; 2.
  DR
  DR
       SMART; SM00409; IG; 3.
       SMART; SM00407; IGc1; 3.
  DR
       SMART; SM00406; IGv; 1.
  DR
       PROSITE; PS50835; IG LIKE; 4.
  DR
       PROSITE; PS00290; IG MHC; UNKNOWN 2.
  DR
  KW
       Hypothetical protein.
                  485 AA; 52472 MW; 81236FF3AD821056 CRC64;
  SO
       SEQUENCE
    Query Match
                            73.6%; Score 529; DB 2;
                                                      Length 485;
    Best Local Similarity
                           71.4%; Pred. No. 2.6e-44;
    Matches 100; Conservative 17; Mismatches
                                                   21; Indels
                                                                  2; Gaps
                                                                             1:
              1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
  Qу
                    1 \ \texttt{MDSRFNLVFLVLILKGVQCDVQLVESGGGLVPPGGSRKLSCAASGFTFSNYGMHWVRQAP} \ \ 60
  Db
             61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--Y 118
  Qу
                61 EKGLEWVAYISSSSGTIFYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARLYY 120
  Db
            119 DHYSGSSDYWGQGTTVTVSS 138
  Qу
                 : | |: ||||||:||||
            121 SNYGGAMDYWGQGTSVTVSS 140
  Db
  RESULT 5
  AAH58814
page. ID
       AAH58814
                   PRELIMINARY;
                                    PRT;
                                           485 AA....
  AC
       AAH58814;
  DT
       02-MAR-2004 (TrEMBLrel. 27, Created)
       02-MAR-2004 (TrEMBLrel. 27, Last sequence update)
  DT
       02-MAR-2004 (TrEMBLrel. 27, Last annotation update)
  DT
       Hypothetical protein.
  DΕ
  OS
       Mus musculus (Mouse).
       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  OC
       Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  OC
  OX
       NCBI TaxID=10090;
  RN
       [1]
       SEQUENCE FROM N.A.
  RP
```

```
STRAIN=FVB/N; TISSUE=Colon;
RC
    MEDLINE=22388257; PubMed=12477932;
RX
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA '
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
    Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
RA
    Jones S.J., Marra M.A.;
    "Generation and initial analysis of more than 15,000 full-length human
RT
RT
    and mouse cDNA sequences.";
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=FVB/N; TISSUE=Colon;
RA
    Strausberg R.;
    Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; BC058814; AAH58814.1; -.
KW
    Hypothetical protein.
               485 AA; 52472 MW; 81236FF3AD821056 CRC64;
SQ
    SEQUENCE
 Query Match
                         73.6%; Score 529; DB 2; Length 485;
 Best Local Similarity
                        71.4%; Pred. No. 2.6e-44;
 Matches 100; Conservative 17; Mismatches
                                                21; Indels
                                                              2; Gaps
                                                                          1;
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qy
                  1 MDSRFNLVFLVLILKGVQCDVQLVESGGGLVPPGGSRKLSCAASGFTFSNYGMHWVRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--Y 118
Qу
             Db
          61 EKGLEWVAYISSSSGTIFYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARLYY 120
         119 DHYSGSSDYWGQGTTVTVSS 138
Qу
              : | |: ||||||:|||
Db
      121 SNYGGAMDYWGQGTSVTVSS 140
RESULT 6
Q91Z05
                PRELIMINARY;
                                 PRT;
                                        473 AA.
ID
    Q91Z05
AC
    Q91Z05;
DT
    01-DEC-2001 (TrEMBLrel. 19, Created)
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
    01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DT
DE
    Expressed sequence AU044919.
GN
    Name=AU044919;
```

```
OS
    Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
     NCBI TaxID=10090;
OX
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=CZECH II;
RC
    TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wntl model.
RC
     Expression driven by an MMTV-LTR enhancer.;
RX
    MEDLINE=22388257; PubMed=12477932;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA.
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
     Jones S.J., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [2]
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=CZECH II;
RC
    TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC
    Expression driven by an MMTV-LTR enhancer.;
RA
     Strausberg R.;
RL
     Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
DR
     EMBL; BC010327; AAH10327.1; -.
    PIR; S68213; S68213.
DR
    HSSP; P01783; 1IGC.
DR
DR
   MGD; MGI:2144967; AU044919.
    InterPro; IPR000345; CytC_heme_BS.
DR
DR
    InterPro; IPR007110; Ig-like.
DR
     InterPro; IPR003597; Ig c1.
DR
     InterPro; IPR003006; Iq MHC.
DR
     InterPro; IPR003596; Ig v.
                                                                    ----
DR
     Pfam; PF07654; C1-set; 3.
DR
     Pfam; PF00047; ig; 1.
DR
     SMART; SM00406; IGv; 1.
     PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
DR
DR
     PROSITE; PS50835; IG LIKE; 4.
DR
     PROSITE; PS00290; IG MHC; UNKNOWN 1.
SQ
     SEQUENCE
                473 AA; 51946 MW; CF625F008932AF12 CRC64;
  Query Match
                          71.8%; Score 516.5; DB 2; Length 473;
                          72.5%; Pred. No. 4.5e-43;
  Best Local Similarity
 Matches 100; Conservative 16; Mismatches 21; Indels
                                                                1; Gaps
                                                                              1;
```

```
1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
· Qy
               1 MDSRLNLVFLVLILKGVQCEVQLVESGGGLVKPGGSRKLSCAASGFTFSDYGMHWVRQAP 60
 Db
 Qy
            61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH 120
               :1 11111 1 11
                                Db
            61 EKGLEWVAYINSGSTTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCAR-EL 119
           121 YSGSSDYWGQGTTVTVSS 138
 Qy
                    Db
           120 WLRRIDYWGQGTTITVSS 137
 RESULT 7
 HV54 MOUSE
      HV54 MOUSE
                     STANDARD;
                                    PRT;
                                          117 AA.
 ID
      P18525;
 AC
 DT
      01-NOV-1990 (Rel. 16, Created)
      01-NOV-1990 (Rel. 16, Last sequence update)
 DT
 DT
      15-JUL-1999 (Rel. 38, Last annotation update)
      Ig heavy chain V region 5-84 precursor.
 DE
      Mus musculus (Mouse).
 OS
      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC
 OC
      Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
      NCBI TaxID=10090;
 OX
 RN
      [1]
      SEQUENCE FROM N.A.
 RP
 RC
      STRAIN=BALB/cJ;
      MEDLINE=89279149; PubMed=2499654;
 RX
      Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
 RA
      "Early onset of somatic mutation in immunoglobulin VH genes during the
 RT
      primary immune response.";
 RT
 RL
      J. Exp. Med. 169:2007-2019(1989).
      -!- MISCELLANEOUS: This sequence belongs to the VH7183 subfamily.
 CC
      PIR; JT0505; HVMS84.
 DR
      HSSP; P01810; 2FBJ.
 DR
 DR
      InterPro; IPR007110; Iq-like.
      InterPro; IPR003596; Ig v.
 DR
      Pfam; PF00047; ig; 1.
 DR
      SMART; SM00406; IGv; 1.
 DR
 DR
      PROSITE; PS50835; IG LIKE; 1.
 KW
      Immunoqlobulin V region; Signal.
 FT
      SIGNAL
                    1
                          19
                   20
                         117
 FT
      CHAIN
                                   Ig heavy chain V region 5-84.
                       .....49
 FT
      DOMAIN
                   20
                                   Framework-1.
                   50
      DOMAIN
                          54
                                   Complementarity-determining-1.
 FT
      DOMAIN
                   55
                          68
                                   Framework-2.
 FT
                   69
                                   Complementarity-determining-2.
      DOMAIN
                          85
 FT
      DOMAIN
                   86
                         117
                                   Framework-3.
 FT
      DISULFID
                   41
                         115
                                  By similarity.
 FT
      NON TER
                  117
                         117
 SQ
      SEQUENCE
                 117 AA; 12872 MW; 234055CB6A469861 CRC64;
    Query Match
                           71.2%; Score 512; DB 1; Length 117;
    Best Local Similarity
                           84.6%; Pred. No. 2.6e-43;
   Matches 99; Conservative
                                 6; Mismatches
                                                      Indels
                                                                 0;
                                                                    Gaps
                                                                            0;
```

```
1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLSLIFLVLVLKGVLCEVKLVESGGGLVQPGGSLKLSCAASGFTFSSYTMSWVRQTP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLOMSSLKSEDTALYYCVR 117
Qу
             61 EKRLEWVAYISNGGGSTYYPDTVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCAR 117
Db
RESULT 8
HV55 MOUSE
    HV55 MOUSE
                   STANDARD;
                                 PRT;
                                        117 AA.
    P18526;
AC
    01-NOV-1990 (Rel. 16, Created)
DT
    01-NOV-1990 (Rel. 16, Last sequence update) 15-JUL-1999 (Rel. 38, Last annotation update)
DT
DT
    Ig heavy chain V region 345 precursor.
DE
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
    SEQUENCE FROM N.A.
RP
RC
     STRAIN=BALB/cJ;
    MEDLINE=89279149; PubMed=2499654;
RX
    Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
RA
     "Early onset of somatic mutation in immunoglobulin VH genes during the
RT
RT
    primary immune response.";
    J. Exp. Med. 169:2007-2019(1989).
RL
    -!- MISCELLANEOUS: This sequence belongs to the VH7183 subfamily.
CC
DR
    PIR; JT0502; HVMS34.
    HSSP; P01783; 1IGC.
DR
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003596; Ig v.
    Pfam; PF00047; ig; 1.
DR
DR
    SMART; SM00406; IGv; 1.
DR
     PROSITE; PS50835; IG LIKE; 1.
KW
    Immunoglobulin V region; Signal.
FT
    SIGNAL
                 1
                        19
    CHAIN
                 20
                       117
                                 Ig heavy chain V region 345.
FT
FT
    DOMAIN
                 20
                        49
                                 Framework-1.
                 50
                                Complementarity-determining-1.
FT
    DOMAIN
                        54
FT
    DOMAIN
                 55
                        68
                                 Framework-2.
                                Complementarity-determining-2.
    DOMAIN
                 69
                        85
FT
FT
    DOMAIN
                 86
                       117
                                 Framework-3.
    DISULFID
FT
                 41
                       115
                                By similarity.
    NON TER
\operatorname{FT}
                117
                       117
    SEQUENCE
               117 AA; 12902 MW; 49380E4627ACA99A CRC64;
SQ
  Query Match
                         70.9%; Score 510; DB 1; Length 117;
  Best Local Similarity
                         83.8%; Pred. No. 4.1e-43;
           98; Conservative
                               6; Mismatches
 Matches
                                                13; Indels
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MNFGLRLIFLVLTLKGVKCEVQLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTP 60
Db
```

```
-Qy
           61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR 117
              Db
           61 EKRLEWVAYISSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCAR 117
RESULT 9
Q91XE1
ID
     Q91XE1
                 PRELIMINARY;
                                   PRT;
                                          480 AA.
     Q91XE1;
AC
     01-DEC-2001 (TrEMBLrel. 19, Created)
DT
     01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
     01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DT
     Igh-VJ558 protein (Fragment).
DE
GN
     Name=Igh-VJ558;
OS
     Mus musculus (Mouse).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
     NCBI TaxID=10090;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     STRAIN=FVB/N; TISSUE=Colon;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
     Jones S.J., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length human
RT
RT
     and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
     [2]
RP
     SEQUENCE FROM N.A.
     STRAIN=FVB/N; TISSUE=Colon;
RC
RA
     Strausberg R.;
     Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RL
DR
     EMBL; BC010798; AAH10798.1; -.
     HSSP; P01789; 1MCP.
DR
     InterPro; IPR007110; Ig-like.
DR
DR
     InterPro; IPR003597; Ig cl.
DR
     InterPro; IPR003006; Ig MHC.
     InterPro; IPR003596; Ig v.
DR
     Pfam; PF07654; C1-set; 2.
DR
     Pfam; PF00047; ig; 1.
DR
     SMART; SM00406; IGv; 1.
```

DR

```
DR
    PROSITE; PS50835; IG LIKE; 4.
    PROSITE; PS00290; IG MHC; UNKNOWN 2.
DR
                         1
    NON TER
\mathbf{FT}
SQ
    SEQUENCE
               480 AA;
                        51936 MW; 20B9234EEF2B41ED CRC64;
                         70.2%; Score 505; DB 2; Length 480;
  Query Match
                                 Pred. No. 6.5e-42;
  Best Local Similarity
                         72.3%;
           99; Conservative 16; Mismatches
                                               20;
                                                    Indels
                                                               2;
                                                                   Gaps
 Matches
           2 NFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNSD 61
QУ
             1 NFGLSLIFLVLILKGVLCDVKLVESGGGLVKPGGSLRLSCAASGFIFSNSYMSWVRQTPE 60
Db
          62 KRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDHY 121
Qу
              61 KRLEWVATISNSGYATHYPDSMKGRFTISRDNAQNTVLLQMTSLNSEDTAVYYCTRGDYW 120
Db
         122 SGSSDYWGQGTTVTVSS 138
QУ
                 121 --YFDVWGAGTTVTVSS 135
Db
RESULT 10
Q96BB9
                                  PRT:
                                         597 AA.
                PRELIMINARY;
    Q96BB9
ΙD
AC
     096BB9;
     01-DEC-2001 (TrEMBLrel. 19, Created)
DT
     01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
     01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DT
     IGHM protein.
DE
OS
     Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
     NCBI TaxID=9606;
OX
RN
     [1] .
     SEQUENCE FROM N.A.
RP
     TISSUE=Primary B-Cells;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA....
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
     Jones S.J., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RT
```

```
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Primary B-Cells;
    Strausberg R.;
RA
    Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; BC015760; AAH15760.1; -.
DR
    PIR; S05271; S05271.
DR
DR
    PIR; S24260; S24260.
    HSSP; P01861; 1ADQ.
DR
    InterPro; IPR007110; Iq-like.
DR
    InterPro; IPR003597; Ig c1.
DR
    InterPro; IPR003006; Ig MHC.
DR
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF07654; C1-set; 4.
DR
DR
    Pfam; PF00047; ig; 1.
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 5.
DR
    PROSITE; PS00290; IG MHC; UNKNOWN 3.
DR
    SEQUENCE 597 AA; 65039 MW; 4FCA3AD8ECE263D9 CRC64;
SQ
                        70.0%; Score 503; DB 2; Length 597;
 Query Match
                        66.7%; Pred. No. 1.3e-41;
 Best Local Similarity
         96; Conservative 22; Mismatches 20; Indels
                                                                         2;
                                                              6; Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MEFGLSWLFLVAILKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFSFSSYAMNWVRQAP 60
Db
          61 \ \mathsf{DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDH \ 120
Qу
              61 GKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSRDTLYLQMNSLRAEDTAVYYCAKDPR 120
Db
         121 -YSGS----SDYWGQGTTVTVSS 138
Qy.
              11 1
                      121 GYSASGNYTREDYWGQGTLVTVSS 144
RESULT 11
HV16 MOUSE
    HV16 MOUSE
                   STANDARD;
                                 PRT;
                                        136 AA.
ΙD
    P01783;
AC
    21-JUL-1986 (Rel. 01, Created)
DT
    21-JUL-1986 (Rel. 01, Last sequence update)
\mathbf{DT}
    01-OCT-2004 (Rel. 45, Last annotation update)
    Ig heavy chain V region MOPC 21 precursor (Fragment).
DE
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    MEDLINE=81234548; PubMed=6788376;
RX
    Bothwell A.L.M., Paskind M., Reth M., Imanishi-Kari T., Rajewsky K.,
RA
RA
     Baltimore D.;
    "Heavy chain variable region contribution to the NPb family of
RT
RT
    antibodies: somatic mutation evident in a gamma 2a variable region.";
```

```
Cell 24:625-637(1981).
RL
RN
     SEQUENCE OF 17-136.
RP
     MEDLINE=77100368; PubMed=401950;
RX
RA
     Adetugbo K., Milstein C., Secher D.S.;
     "Molecular analysis of spontaneous somatic mutants.";
RT
     Nature 265:299-304(1977).
RL
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     _____
CC
     EMBL; J00522; AAD15290.1; -.
DR
     PIR; E90809; G1MS21.
DR
     PDB; 1IGC; X-ray; H=-.
DR
     InterPro; IPR007110; Ig-like.
DR
     InterPro; IPR003596; Ig v.
DR
DR
     Pfam; PF00047; ig; 1.
     SMART; SM00406; IGv; 1.
DR
     PROSITE; PS50835; IG LIKE; 1.
DR
     3D-structure; Direct protein sequencing; Immunoglobulin V region;
ΚW
KW
     Signal.
FT
     NON TER
                   1
                           1
     SIGNAL
                   <1
                          16
FT
                                    Ig heavy chain V region MOPC 21.
                   17
                         136
FT
     CHAIN
     DOMAIN
                  115
                         119
                                    D segment.
FT
                  120
                                    JH4 SEGMENT.
FT
     DOMAIN
                         136
                   38
                         112
FT
     DISULFID
                   75
                          78
                                    HYAD -> DYAH (in Ref. 2).
FT
     CONFLICT
                                    DN \rightarrow ND (in Ref. 2).
     CONFLICT
                  89
                          90
                                    W \rightarrow H \text{ (in Ref. 2)}.
     CONFLICT
                  115
                         115
FΤ
                                    Y \rightarrow W \text{ (in Ref. 2)}.
     CONFLICT
                  120
                         120
FT
                   19
                          23
FT
     STRAND
                   26
     STRAND
                          28
FT
                   30
FT
     TURN
                           31
                   34
                           41
FT
     STRAND
                   45
     HELIX
                           47
FT
                   50
                           55
FT
     STRAND
                   61
                           67
FT
     STRAND
                   69
                           70
FT
     TURN
                           76
                   74
     STRAND
\mathbf{FT}
FT
     HELIX
                   7.8
                           80
                   81
                           81
FT
     STRAND
FT
     TURN
                   82
                           83
                           89
                   84
\operatorname{FT}
     STRAND
                   90
                           93
     TURN
FΤ
FT
     STRAND
                   94
                           99
                  104
                          106
     HELIX
FT
                  108
                          114
\operatorname{FT}
     STRAND
                  118
                          119
FT
     TURN
FT
     STRAND
                  125
                          126
                          134
FT
     STRAND
                  130
                  136
                          136
     NON TER
```

```
136 AA; 15071 MW; 2276A98DBDBF7016 CRC64;
     SEQUENCE
SQ
                         69.9%; Score 502.5; DB 1;
                                                     Length 136;
  Query Match
                         70.4%; Pred. No. 2.8e-42;
  Best Local Similarity
          95; Conservative 20; Mismatches
                                               19;
                                                     Indels
                                                               1;
                                                                  Gaps
                                                                          1;
           5 LSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNSDKRL 64
Qу
             2 LNLVFLVLILKGVQCDVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGL 61
Db
          65 EWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVRYDHYS-G 123
Qу
                         Db
          62 EWVAYISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARWGNYPYY 121
         124 SSDYWGQGTTVTVSS 138
Qу
             122 AMDYWGQGTSVTVSS 136
Db
RESULT 12
HV59 MOUSE
    HV59 MOUSE
                   STANDARD;
                                  PRT;
                                        117 AA.
ID
     P18530;
AC
     01-NOV-1990 (Rel. 16, Created)
DT
DT
     01-NOV-1990 (Rel. 16, Last sequence update)
     15-JUL-1999 (Rel. 38, Last annotation update)
DT
DE
     Ig heavy chain V region 7-39 precursor.
     Mus musculus (Mouse).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
     NCBI TaxID=10090;
RN
     [1]
     SEQUENCE FROM N.A.
RΡ
     STRAIN=BALB/cJ;
RC
     MEDLINE=89279149; PubMed=2499654;
RX
     Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
RA
     "Early onset of somatic mutation in immunoglobulin VH genes during the
RT
RT
     primary immune response.";
     J. Exp. Med. 169:2007-2019(1989).
RL
     -!- MISCELLANEOUS: This sequence belongs to the VH7183 subfamily.
CC
     PIR; JT0507; HVMS39.
DR
DR
     HSSP; P18529; 118K.
     InterPro; IPR007110; Ig-like.
DR
     InterPro; IPR003596; Ig_v.
DR
DR
     Pfam; PF00047; ig; 1.
DR
     SMART; SM00406; IGV; 1.
     PROSITE; PS50835; IG_LIKE; 1.
DR
     Immunoglobulin V region; Signal.
KW
FT
     SIGNAL
                  1
                        19
                       117
     CHAIN
                 20
                                 Iq heavy chain V region 7-39.
FΤ
FT ·
     DOMAIN
                 20
                        49
                                 Framework-1.
                 50
                        54
                                 Complementarity-determining-1.
FT
     DOMAIN
                 55
                        68
                                 Framework-2.
FT
     DOMAIN
                 69
                        85
                                 Complementarity-determining-2.
FT
    DOMAIN
     DOMAIN
                 86
                       117
                                 Framework-3.
FΤ
     DISULFID
                 41
                       115
                                 By similarity.
FT
                       117
FT
     NON TER
                117
```

```
117 AA; 12972 MW; D5CA4167D0F1774F CRC64;
SO
     SEQUENCE
  Query Match
                         69.7%;
                                 Score 501; DB 1; Length 117;
  Best Local Similarity
                         82.9%;
                                Pred. No. 3.3e-42;
          97; Conservative
                                5; Mismatches
                                                15;
                                                      Indels
                                                                0;
                                                                  Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
              Db
           1 MNFGLSLIFLVLILKGVQCEVKWVESGGGSVKPGGSLKLSCEASGFTFSNYGMSWVROTP 60
           61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR 117
Qу
              : | | | | | | | |
                             Db
           61 EKRLEWVASISGGVSYTYYPDSVKGRFTISRDNAKNNLYLQMNSLTSEDTALYYCAR 117
RESULT 13
Q6PI81
ID
     Q6PI81
                PRELIMINARY;
                                  PRT;
                                         478 AA.
AC
     Q6PI81;
DT
     05-JUL-2004 (TrEMBLrel. 27, Created)
     05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT
DT
     05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE
     Hypothetical protein.
OS-
     Homo sapiens (Human).
OC.
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     TISSUE=Primary B-Cells;
     MEDLINE=22388257; PubMed=12477932;
RX
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
     Jones S.J., Marra M.A.;
     "Generation and initial analysis of more than 15,000 full-length human
RT
RT
     and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
RP
     SEQUENCE FROM N.A.
RC
     TISSUE=Primary B-Cells;
RA
     Strausberg R.;
RL.
     Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
     EMBL; BC041037; AAH41037.1; -.
```

0;

```
DR
       InterPro; IPR003599; Iq.
       InterPro; IPR007110; Ig-like.
  DR
  DR
       InterPro; IPR003597; Ig c1.
       InterPro; IPR003006; Ig MHC.
  DR
       InterPro; IPR003596; Ig v.
  DR
  DR
       Pfam; PF07654; C1-set; 3.
       Pfam; PF00047; iq; 4.
  DR
       SMART; SM00409; IG; 2.
  DR
       SMART; SM00407; IGc1; 3.
  DR
  DR
       SMART; SM00406; IGv; 1.
       PROSITE; PS50835; IG LIKE; 4.
  DR
       PROSITE; PS00290; IG MHC; UNKNOWN 2.
  DR
  KW
       Hypothetical protein.
       SEQUENCE
  SQ
                 478 AA; 52666 MW; 17BED38D917970D6 CRC64;
    Query Match
                           69.4%; Score 499; DB 2; Length 478;
    Best Local Similarity
                           65.5%; Pred. No. 2.6e-41;
    Matches
             97; Conservative 18; Mismatches
                                                  23;
                                                       Indels
                                                                10;
                                                                    Gaps
                                                                            1;
              1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
  Qу
                  Db
             1 MELGLSWVFLVAILEGVQCEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAP 60
             61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117 0
  Qу
                Db
             61 GKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREFE 120
            118 -----YDHYSGSSDYWGQGTTVTVSS 138
  Qy
                       1:1
                              1 | | : | | | | | | | |
           121 STMTTVNADYYYFYMDVWGKGTTVTVSS 148
  Db
  RESULT 14
  AAH41037
  ID
       AAH41037
                  PRELIMINARY;
                                    PRT;
                                          478 AA.
  AC
       AAH41037;
       02-MAR-2004 (TrEMBLrel. 27, Created)
       02-MAR-2004 (TrEMBLrel. 27, Last sequence update)
       02-MAR-2004 (TrEMBLrel. 27, Last annotation update)
  DT
       Hypothetical protein.
  DE
  OS
       Homo sapiens (Human).
       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  OC
  OC
       Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  OX
       NCBI TaxID=9606;
  RN
RP
       SEQUENCE FROM N.A.
  RC
       TISSUE=Primary B-Cells;
       MEDLINE=22388257; PubMed=12477932;
  RX
  RA
       Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
       Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
  RA
  RA
       Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
  RA
       Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
       Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
       Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
  RA
       Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
  RA
       Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
  RA
  RA
       Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
```

```
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
    Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
    Jones S.J., Marra M.A.;
RA
    "Generation and initial analysis of more than 15,000 full-length human
RT
    and mouse cDNA sequences.";
RT
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
    [2]
    SEQUENCE FROM N.A.
RΡ
    TISSUE=Primary B-Cells;
RC
RA
    Strausberg R.;
    Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; BC041037; AAH41037.1; -.
DR
KW
    Hypothetical protein.
SQ
    SEQUENCE
               478 AA; 52666 MW; 17BED38D917970D6 CRC64;
                         69.4%; Score 499; DB 2; Length 478;
  Query Match
                               Pred. No. 2.6e-41;
  Best Local Similarity
                         65.58;
                                                              10; Gaps
 Matches
           97; Conservative
                             18; Mismatches
                                                23; Indels
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MELGLSWVFLVAILEGVQCEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAP 60
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
Qу
              61 GKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREFE 120
         118 -----YDHYSGSSDYWGQGTTVTVSS 138
Qу
                     |:|
                            | | | : | | | | | | |
          121 STMTTVNADYYYFYMDVWGKGTTVTVSS 148
RESULT 15
Q6GMY2
    Q6GMY2
                PRELIMINARY;
                                  PRT;
                                         606 AA.
ID
     Q6GMY2;
AC
     05-JUL-2004 (TrEMBLrel. 27, Created)
DT
     05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT
     05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DT
DE
     Hypothetical protein.
OS
    .Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A.
     TISSUE=Primary B-Cells;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
```

```
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
    Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
    Jones S.J., Marra M.A.;
RA
    "Generation and initial analysis of more than 15,000 full-length human
RT:
    and mouse cDNA sequences.";
RT
RL
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Primary B-Cells;
    Strausberg R.;
RA
    Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; BC073758; AAH73758.1; -.
DR
DR
    InterPro; IPR003599; Ig.
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig_c1.
DR
DR
    InterPro; IPR003006; Ig MHC.
DR
    InterPro; IPR003596; Ig v.
    Pfam; PF07654; C1-set; 4.
DR
    Pfam; PF00047; ig; 4.
DR
    SMART; SM00409; IG; 2.
DR
    SMART; SM00407; IGc1; 4.
DR
    SMART; SM00406; IGV; 1.
DR
    PROSITE; PS50835; IG LIKE; 5.
DR
    PROSITE; PS00290; IG MHC; UNKNOWN 3.
DR
    Hypothetical protein.
KW
               606 AA; 66184 MW; B6B38B51114E4C55 CRC64;
SQ
    SEQUENCE
                         68.9%; Score 495.5; DB 2;
                                                    Length 606;
 Query Match
                         63.6%; Pred. No. 7.6e-41;
 Best Local Similarity
                             18; Mismatches
                                                                         2;
 Matches
           98; Conservative
                                               21;
                                                    Indels
                                                             17; Gaps
           1 MNFGLSLIFLVLVLKGVQCEVKLVESGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQNS 60
Qу
             1 MEFGLSWVFLVAIIKGVQCQVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAP 60
Db
          61 DKRLEWVASIRSGGGRTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCVR--- 117
Qу
                            | |||: | |
          61 GKGLEWVSYISSSSSYTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGN 120
         118 -----YDHYSGSSDYWGQGTTVTVSS 138
Qу
                          121 GIAAAGRVVYAEDYYYYYG-MDVWGQGTTVTVSS 153
```

Search completed: December 13, 2004, 19:17:46 Job time: 133.356 secs